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ABSTRACT 
Pharmacogenomics, the interaction of genes and medications that effect medication-related 
phenotypes such as efficacy, toxicity, and sensitivity reactions, is playing an increasing role in 
medication decision making as we seek more personalized medical care. As key experts in 
supporting medication-decision making, pharmacists are well-positioned to support the 
incorporation of pharmacogenomics into clinical care. Pharmacists desire trustworthy 
information resources that efficiently impart clinically relevant pharmacogenomics information 
to help them make informed recommendations. Clinical interpretation of pharmacogenomics 
genotypes and phenotypes is difficult, and clinicians feel that current resources do not 
adequately support pharmacogenomics-related decision making. We aim to develop 
information resources that provide pharmacists with comprehensive, usable, and actionable 
pharmacogenomic information that that they trust.  
We assert that our project is significant in three ways. First, we developed a detailed 
and clinically relevant pharmacogenomics semantic model to annotate FDA product labels. 
Second, we demonstrate the effectiveness of using qualitative methods to design clinically 
relevant pharmacogenomics information resources that are highly usable by clinicians. Third, 
we demonstrate that our information resource based on our semantic model allows 
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pharmacists to use FDA-approved pharmacogenomics information more efficiently to answer 
questions faster, more correctly, and more easily in terms of usability than the FDA Table of 
Pharmacogenomics Biomarkers in Product Labeling and the FDA Drug Labeling section of 
PharmGKB.org  
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1.0  INTRODUCTION 
Pharmacogenomics, the interaction between gene variants and medications, has the potential 
to revolutionize the way medications are prescribed[1]. At the time of this writing, 
pharmacogenomics research has identified over 130 gene variants that can alter the safety 
and/or effectiveness of drug treatments[2]. Some hospitals have begun using genotype 
information to inform drug and dose selection for several drugs including warfarin[3,4] and 
clopidogrel[5,6]. As genotyping becomes more common, more pharmacists and physicians will 
encounter pharmacogenomic information. To use this information effectively, clinicians will 
need clear, relevant information that will help them interpret complex interactions between 
patient genotypes, resulting phenotypes, and medications, and avoid adverse events and 
improve patient outcomes[7,8].  
At the time of this writing, the FDA recognizes 47 distinct genes that affect medications, 
resulting in different phenotypes when a patient takes an affected medication. These 
phenotypes can be grouped into categories, such as pharmacokinetic and pharmacodynamic 
phenotypes. For instance, some genes affect metabolism. A patient with one variant of a 
metabolism gene might metabolize the drug faster than normal, while another patient with a 
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different variant of the same gene might metabolize it slower. Other genes affect the way the 
drug impacts the body. Certain patients experience an increased risk of a hypersensitivity 
reaction, and for others, a medication may be ineffective for them because they do not have 
the necessary receptor.  
The introduction of pharmacogenomics into clinical practice is important for many 
reasons related to drug safety, efficacy and effectiveness, including reducing the risk of adverse 
drug events related to drug response variability[1]. Adverse drug events account for 
approximately 31% (36,397 out of 117320) unplanned hospital admissions[9] in the United 
States. The adverse drug event problem is multi-faceted: many factors play a role in causing 
medication injuries, including clinical reasons and information gaps in care. Clinical factors 
include drug-drug interactions[10] and variability of patient response to medications[11], while 
information gaps include lack of dissemination of drug knowledge and lack of patient data[12]. 
Identifying patients with variable medication responses could reduce some ADEs by using 
genetic information to ensure the right drug goes to the right patient in the right dose. 
A substantial portion of response variability can be explained by genetic variants 
identified by advances in genomics[11]. An example of this drug response variability is warfarin, 
which has a narrow therapeutic window that varies widely among patients. Depending on the 
patient’s genotype, a physician might choose a starting dose as low as 0.5 mg or as high as 7 mg 
(Table 1)[13] . To prescribe the appropriate dose, a physician needs the patient’s genotype 
results for two different biomarker tests, and he or she must understand how to interpret the 
results. This information is in addition to other factors that affect warfarin dosing such as age, 
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weight, and concomitant medications. The complexities of genotype interpretation with 
warfarin dosing increase the risk of adverse events for the patient: an overdose could result in a 
bleeding episode that could cause unplanned hospital admissions or even death, and an 
insufficient dose could result in ineffective anticoagulation, possibly causing a heart attack, 
stroke, or death.  
Table 1: Three Ranges of Expected Maintenance Warfarin Daily Doses Based on CYP2C9 and VKORC1 
Genotypes[13] 
VKORC1 CYP2C9 
*1/*1 *1/*2 *1/*3 *2/*2 *2/*3 *3/*3
GG 5-7 mg 5-7 mg 3-4 mg 3-4 mg 3-4 mg 0.5-2 mg 
AG 5-7 mg 3-4 mg 3-4 mg 3-4 mg 0.5-2 mg 0.5-2 mg 
AA 3-4 mg 3-4 mg 0.5-2 mg 0.5-2 mg 0.5-2 mg 0.5-2 mg 
With the help of genetic tests, clinicians can ideally prescribe the right dose of the right 
drug at the right time to the right patient. In some cases, such as warfarin[3] and clopidogrel[5], 
genotyping already informs drug and dose selection in select hospitals[3,5]. However, 
medication-related genetic testing is still in its nascent phase[14], and consensus does not yet 
exist on the usefulness of pharmacogenomics versus other methods to determine drug choice 
or dosage[4,15–17], further complicating how to use genetic information. Effective 
presentation of risk information is still an obstacle[18]. As pharmacogenomics becomes more 
integrated into standard practice, clinicians have an ever greater need for clinically relevant, 
effectively presented, searchable information that supports accurate interpretation and 
adoption of treatment recommendations[19].  
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1.1 SIGNIFICANCE 
1.1.1 Pharmacogenomics Implications 
Pharmacogenomics presents a complex picture involving interactions between genes, 
medication exposure, and patient factors to produce phenotypes[20]. Specifically, variations in 
genes can impact drug effects, such as response, efficacy, and risk of adverse effects in many 
therapeutic areas [21]. Each combination presents a unique set of considerations [22,23]. These 
variants can be used to predict who will most likely and least likely benefit from a drug, which 
dose is optimal, or who is at greatest risk of experiencing an unintended adverse drug events 
such as toxicity or failed efficacy[24,25]. Applying this information to individual patients 
presents multiple challenges, including unfamiliar and potentially confusing notation for 
describing gene variants and phenotypes, and interpreting the impact of the gene variants on 
prescribing decisions. When presented with a patient with a genotype that might influence the 
efficacy or safety of a medication under consideration, the prescriber must incorporate 
information about the gene, the gene variant, how the transcribed protein interacts with any 
particular drug, and other typical patient clinical variables like age, weight, comorbidities, and 
concomitant medications to determine the best course of action[26].  
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Gene variants can affect a patient’s risk of adverse drug events in two ways: drug 
exposure and drug response[27]. Drug exposure is how much of the drug the patient receives, 
which can be influenced by the dose and the pharmacokinetics profile (absorption, distribution, 
metabolism, and excretion). Drug response is the pharmacodynamics profile of the drug, or the 
collection of effects, intended and unintended, that the drug has on the body. Drug response 
includes both intended effectiveness and adverse effects, such as toxicity and allergic 
reactions[24]. Applying knowledge of the interaction between genotypes and medications to 
inform medication and dosage choice can optimize treatment and prevent adverse medication 
events[28], yet that knowledge is not regularly applied[29,30].  
Consequences of not knowing a patient’s genotype and resulting phenotype can be 
severe, even fatal, as in the death of a breastfed newborn whose mother was an ultra-rapid 
metabolizer of codeine, which caused her breast milk to contain toxic levels of codeine’s active 
metabolite, morphine[31]. As a result, breastfeeding mothers are typically not prescribed 
codeine. Another drug, clopidogrel, has reduced effectiveness for some patients. The FDA now 
requires the boxed warning section of the clopidogrel product label to warn that poor 
metabolizers of clopidogrel may not be effectively treated by the drug, and may have a higher 
risk of heart attacks, strokes, and death than normal metabolizers[32], implying that genetic 
testing may be appropriate prior to prescription.  In one more example, Epstein et al. found 
that integrating warfarin genotyping into the clinical workflow reduced the risk of 
hospitalization in the six months following therapy initiation by 31%. (adjusted hazard ratio 
6 
[HR]: 0.69, 95% CI: 0.58 to 0.82)[33]. These examples are only a fraction of the drugs that have 
pharmacogenomics implications.  
Table 2: Pharmacokinetic Phenotypes 
Phenotype Phenotype description Genotype description 
Ultra-rapid metabolizer Increased enzyme activity 
compared to rapid metabolizers 
Two increased function alleles, or more than 
two normal function alleles 
Rapid metabolizer Increased enzyme activity 
compared to normal metabolizers 
but less than ultra-rapid 
metabolizers 
Combinations of normal function and 
increased function alleles 
Normal Metabolizer Fully functional enzyme activity Combination of normal function, decreased 
function, and/or no function alleles 
Intermediate 
metabolizer 
Decreased enzyme activity (activity 
between normal and poor 
metabolizer) 
Combination of normal function, decreased 
function, and/or no function alleles 
Poor metabolizer Little to no enzyme activity Combination of no function alleles and/or 
decreased function alleles 
At this time, the metabolism subset of pharmacokinetic phenotypes are the best 
characterized pharmacogenomics phenotypes (Table 2)[34]. A normal metabolizer, also 
referred to as an extensive metabolizer, is the phenotype that exhibits a normal metabolism 
rate, and is the phenotype to which the other phenotypes are compared. A poor metabolizer 
exhibits a slower metabolism rate than the normal population. This phenotype usually exhibits 
at least one nonfunctional allele of the drug metabolizing enzyme. An intermediate metabolizer 
also exhibits a slower metabolism rate than the normal population, but not necessarily as slow 
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as a poor metabolizer. An intermediate metabolizer is likely to carry at least one partially-
functioning allele of the drug metabolizing enzyme. A rapid metabolizer has increased 
metabolism activity compared to normal metabolizers, but less than ultra-rapid metabolizers. 
An ultra-rapid metabolizer is the phenotype that exhibits a faster than normal metabolism rate. 
The ultra-rapid metabolizer phenotype is likely to carry at least one allele with enhanced 
enzyme activity, or multiple copies of normal function alleles. As the number of copies of the 
allele increases, the rate of metabolism also increases[34]. 
These phenotypes appear simple to interpret, but the interpretation is complicated by 
the interaction between the variant and the medication. For example, per the Food and Drug 
Administration (FDA) and Clinical Pharmacogenetics Implementation Consortium (CPIC) 
guidelines, a poor metabolizer (CYP2C19*2/*2) of clopidogrel should not be given clopidogrel, 
but given an alternate therapy such as prasugrel[35]. The same poor metabolizer should be 
given a 50% reduced starting dose of amitriptyline[36]. Further complicating matters is a recent 
study that found that CYP2C19 poor metabolizers can be given clopidogrel, but they need up to 
4 times the normal dose for it to be effective[37]. These differences among recommendations 
of how to manage patients with important pharmacogenomic variants are introduce a 
significant challenge of interpretation for the clinician. 
1.1.2 History of pharmacogenomics* in clinical practice 
Gene-medication interactions have been observed since 1969, when the first 
pharmacogenonomic biomarker was identified. Patients deficient in glucose-6-phosphate 
*Pharmacogenetics and pharmacogenomics are terms used interchangeably to refer to the same concept, but pharmacogenomics is the
broader term that encompasses both genetics and genomics. For the purposes of this thesis, I will use pharmacogenomics, but citations may 
refer to pharmacogenetics.  
8 
dehydrogenase developed hemolysis if they were given primaquine[38]. Other drugs have been 
known to be metabolized at different rates in different patients, but the genetic factors 
influencing the metabolism were not well understood. For instance, researchers knew that 
variability existed in rates of metabolism of drugs such as tolbutamide[39], debrisoquine[40], 
and desipramine[41], to name a few. Clinicians and researchers have been aware of these 
phenotypes, but they had no way of testing for them prior to prescribing the patient the drug. 
The advent of assays for the gene variants has made genetic-based treatment decisions 
available to the individual patient.  
In 2003, De Leon, et al. introduced the Amplichip CYP450 Test, which used microarray 
technology to perform CYP2D6 and CYP2C19 genotyping[42]. This was the first combination 
pharmacogenomic test available, and was FDA approved in January 2005. de Leon genotyped 
4532 psychiatric patients. His laboratory successfully performed 94% of assays for CYP2D6 and 
98% of assays for CYP2C19. They found practical issues with DNA collection and testing due to 
insufficient saliva and blood collection that contributed to the 6% and 2% respective failure 
rates. AmpliChip was groundbreaking as the first step toward clinical application of 
pharmacogenomics because it directly identifies 27 allelic variants of CYP2D6 and 3 allelic 
variants for CYP2C19 in only one test. Previous, more expensive, tests required 30 individual 
tests for each allele, requiring a much larger sample volume.  
In 2004, Donald Gardner proposed that genomic information regarding the CYP450 
enzyme could be used to predict drug interactions and avoid adverse drug events. CYP450 
refers to a group of enzymes that are well-established as being part of the metabolic and 
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bioactivation pathway of many drugs. Multiple known polymorphisms of these genes result in 
variation in drug metabolism and response. Gardner demonstrated, prior to the availability of 
commercial, clinical genetic tests for pharmacogenomic variants, that it is possible to apply 
both patient-specific genomic information and drug interactions information to provide clinical 
decision support to improve medication management and reduce the risk of adverse drug 
events[43]. 
Developing clinical guidelines for use of these genetic variants in practice was the next 
step toward clinical application of pharmacogenomics. de Leon et al. drafted clinical guidelines 
for psychiatrists to direct their use of pharmacogenomic testing for CYP2D6 and CYP2C19, as 
well as how to treat patients who are identified as poor metabolizers[44]. They suggest that 
patients with a history of adverse drug events that point to being poor metabolizers, such as a 
serious case of neuroleptic malignant syndrome or priapism, be considered for genotyping. 
Other patients, such as those claiming that multiple drugs are ineffective or intolerable, or 
those who do not respond to drugs that are not metabolized by CYP2D6 or CYP2C19, were not 
candidates for genotyping.  
Metabolism-related pharmacogenes are not the only clinically-relevant phenotypes. 
Oncology is another area where biomarker information has allowed physicians to tailor 
treatments to their patients. For instance, the presence of epidermal growth factor receptor 
(EGFR) on tumor cells indicates that patients would benefit from treatment by certain cancer 
drugs, such as afatinib and erlotinib[45]. These genes help guide treatment decisions, much like 
non-oncology genes guide decisions. However, oncology pharmacogenes differ from non-
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oncology genes because the gene expression is tumor tissue specific, rather than a germ-line 
gene that a person carries all their life in every cell. The tumor gene expression can change over 
time, unlike germ-line genes. Cancer cells can express different combinations of 
pharmacogenes in different levels, which complicates decision making.  
In 2000, the National Institute of Health funded the Pharmacogenomics Research 
Network (PGRN) (www.pgrn.org)[46] to advance pharmacogenomics discoveries nationally and 
internationally through collaborative research of drug response genes. Six sites are 
implementing pharmacogenomics testing (University of Maryland, University of Florida, 
Vanderbilt University, St. Jude Children’s Hospital, Ohio State University, and Mayo Clinic) and 
guideline development to overcome these barriers and enact pharmacogenomics knowledge in 
clinical care.  In 2005, the Dutch Pharmacogenetics Working Group (DPWG) was established by 
the Royal Dutch Pharmacist's Association (KNMP) to develop guidelines and recommendations 
for pharmacogenomics-based treatment decisions[47] in Europe. In 2011, the Clinical 
Pharmacogenetic Implementation Consortium (CPIC) began developing clinical guidelines to 
support biomarker-based clinical decision making, in conjunction with the Pharmacogenomics 
Knowledgebase (www.pharmgkb.org) and PGRN. Other networks include the eMERGE network, 
which consists of 11 sites attempting to implement pharmacogenomics clinical decision support 
(CDS)[48]. The goal of these organizations is to research and implement clinical 
pharmacogenomics testing and decision making. 
As of October, 2015, the U.S. Food and Drug Administration (FDA) has identified 47 
biomarkers that affect 137 medications[24]. The FDA’s “Table of Pharmacogenomic Biomarkers 
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in Drug Labels”[21] provides an overview of these details, including pointers to sections of 
medication product labels that describe pharmacogenomics implications. In 2011, the FDA 
published an Industry Guidance describing when genomic information should be considered 
during drug development and regulatory review. The guidance informs pharmaceutical 
companies on how to include pharmacogenomic data and design studies during drug 
development, to better inform subsequent use of the drug in populations with affected 
variants. The guidance also specifies to pharmaceutical companies what pharmacogenomic 
information should be mentioned in product labeling, including polymorphic enzyme 
descriptions, population frequencies, positive and negative predictive values associated with 
biomarkers, effect of the variant on pharmacokinetic profiles, the evidence supporting the 
genetic basis of response variability, and dose changes based on genotype. The guidance 
represents an important communication in the use of pharmacogenomic data in drug 
discovery, drug deployment, and clinical application of pharmacogenomic knowledge[24].  
The last step to move pharmacogenomics into clinical care is establishing the 
effectiveness of genetic testing to tailor drug decisions to individual patients, which requires 
significant investment in genetic research for precision medicine. In 2015, President Barack 
Obama introduced the Precision Medicine Initiative, with the intent of using genetic 
information to cure diseases and identify the best treatments for individual patients. As a result 
of that initiative, the director of the National Institutes of Health, Dr. Francis Collins, 
implemented the Precision Medicine Initiative Cohort Program. This program will enroll a 
million patients nationwide as a research cohort to accelerate the understanding of health and 
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disease, including how to tailor medications to specific patients[49]. Clearly, broad support 
exists scientifically, clinically, and now politically for using genetic information to provide 
tailored care to patients. Pharmacogenomics is a critical first step in achieving precision 
medicine. 
1.1.3 Stakeholders’ Views of Pharmacogenomics in Practice 
The lack of pharmacogenomics genotype testing in most health care systems prevents the 
realization of personalized medicine[22,50]. Poor adoption is not solely based on cost. The price 
of genotyping continues to fall, and with the advent of whole genome sequencing, a patient can 
be sequenced once and the information will be relevant for the rest of his or her life, making 
the acquisition of this information affordable[51]. As a result, genotyping will become common 
practice[19,23,52,53]. Physicians, nurses, and pharmacists will encounter genotype results in 
their practice, and will need to understand how to interpret and implement the information 
they receive.  
Lack of appropriate education and information might contribute to poor adoption of 
pharmacogenomics. Studies have shown that physicians feel poorly informed about 
pharmacogenomics testing and that they have a difficult time interpreting test results[14,30]. In 
a large survey of physicians, Stanek et al. found that 12.9% of respondents ordered or 
recommended a pharmacogenomic genetic test in the previous 6 months[14]. Of those who 
had not ordered genetic tests, 67.1% said that they did not order them because they did not 
feel adequately informed about the test or the results.  
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Pharmacists expect that both physicians and pharmacists will have to play a role in 
pharmacogenomics test interpretation[54]. In semi-structured interviews of pharmacists, Dias 
et al found that almost all (18/21) felt that lack of training in pharmacogenomics was a barrier 
to pharmacogenomics use. As clinicians with extensive training in pharmacology, drug 
selection, drug dose and drug-drug interactions, pharmacists are poised to be leaders in 
integration of pharmacogenomics in clinical practice[55,56]. They want to recommend 
pharmacogenomic testing and employ the results in their clinical advice[57]. Pharmacists feel 
that they and their profession as a whole would benefit from pharmacogenomics 
instruction[58,59]. In a study assessing physician attitudes toward pharmacogenomic decision 
support during medication prescribing, Overby et al. found that internal medicine physicians 
are generally positive about genomic medicine in prescribing, but they lack sufficient 
knowledge and personal comfort with interpreting and using genetic information[60]. 
The PGRN Translational Pharmacogenetics Program identified seven barriers to 
adoption of pharmacogenomics testing in clinical practice: 1) lack of ability to perform 
genotype testing quickly in a Clinical Laboratory Improvement Amendments - compliant 
laboratory (CLIA); 2) lack of genotype test result standardization in electronic medical records 
(EMRs); 3) lack of pharmacogenomics randomized clinical trials validating treatment algorithms; 
4) lack of clinicians’ ability to interpret and use pharmacogenomics information; 5) lack of clear 
pharmacogenomics testing recommendations; 6) lack of pharmacogenomics clinical decision 
support infrastructure; and 7) cost and reimbursement concerns[61].  
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At Vanderbilt, one of the PGRN sites, the Pharmacogenomic Resource for Enhanced 
Decisions in Care and Treatment (PREDICT) program has genotyped approximately 3000 
patients who were scheduled for cardiac catheterization to determine their CYP2C19 variant 
status prior to administration of clopidogrel[5] and provided that information with decision 
support to clinicians via the EMR. PREDICT demonstrates the feasibility of implementing 
pharmacogenomics testing as a strategy for personalized medicine. PREDICT was formed in 
2009, and CYP2C19 testing began in 2011. The project involved coordination of cardiologists, 
patients, EMR technical staff, geneticists, informaticists, user interface experts, pharmacists, 
pharmacologists, clinical pathologists, program managers, the Medical Center ethics 
committee, and the organization of a CLIA-certified molecular diagnostics laboratory. It cost $5 
million over 2 years to develop and implement.  
The University of Maryland has implemented the Personalized Anti-Platelet 
Pharmacogenetics Program (PAP3) as part of the PGRN program [62]. They offer CYP2C19 
genetic testing to cardiac catheterization patients. As of December 2013, they have approached 
203 patients, 166 of whom consented to genetic testing. Of those, 39.1% were intermediate or 
poor metabolizers, and 17 patients were prescribed alternative therapy. No further results on 
this work have been published at the time of this writing. 
Other efforts have centered on pharmacogenomics alerting in electronic medical 
records. St. Jude’s Children’s Research Hospital, another PGRN site, has developed an active 
clinical decision support (CDS) tool for pharmacogenomic test results. They developed 35 
pharmacogenomics rules for two biomarkers and eight medications, and found that the alerts 
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appropriately guided prescribing in 95% of patients[63]. A group at the University of Utah 
studied how to present genotype information to clinicians in the electronic medical record 
(EMR) as a form of decision support. Using CYP2C9 genotype information, they found that both 
SNP and allele representations of genetic information are effective, but SNP results contain 
more information that could be accessed in the future for reinterpretation[64].  
These efforts remain admittedly United States centered. The Dutch Pharmacogenetics 
Working Group and the European Pharmacogenetics Implementation Consortium are 
addressing pharmacogenomics implementation efforts in Europe. At this time, we are not 
aware of comparable efforts in Asia. 
Clinical decision support for pharmacogenomics is an important aspect of achieving 
pharmacogenomics in clinical care, but it requires the support of the health system and EMR 
development team to enact it. These programs demonstrate the extensive health system 
coordination that is necessary to fully implement this knowledge into clinical care.  
 
1.1.4 Medication prescription information needs 
Information resource designers must understand clinicians’ pharmacogenomics-related 
information needs during the prescribing process to develop resources that communicate 
pharmacogenomics knowledge effectively[65]. At this time, to the best of our knowledge, the 
information needs of clinicians, specifically pharmacists, when engaging with genetic 
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information during drug decision-making, have not been studied. Technical requirements for 
moving genomic information into clinical care have been identified by Masys, et al[66]: 
1) Maintain separation of primary molecular observations from the clinical
interpretations of those data.
2) Support lossless data compression from primary molecular observations to
clinically manageable subsets.
3) Maintain linkage of molecular observations to the laboratory methods used to
generate them.
4) Support compact representation of clinically actionable subsets for optimal
performance.
5) Simultaneously support human-viewable formats and machine-readable formats
in order to facilitate implementation of decision support rules.
6) Anticipate fundamental changes in understanding human molecular variation.
7) Support both individual clinical care and discovery science.
However, those requirements focus on data structure rather than on the specific types of 
information necessary. 
Multiple studies have examined the generic information needs of clinicians[67–71]. A 
systematic review of the information seeking behaviors of physicians found that physicians use 
a wide range of information resources, including reference texts, primary sources, and Internet 
search engines, but overwhelmingly rely on tertiary, scholarly knowledgebase resources[71]. 
Others have studied pharmacists’ information needs: Wong et al. surveyed pharmacists in 
Singapore about where they find drug information[72]. Investigators found that pharmacists 
overwhelmingly use reference texts, which they rated as very or somewhat comprehensive. 
Fewer respondents said that they used websites or search engines, which were rated as less 
comprehensive than reference texts. A survey of Swiss community pharmacists supported 
Wong’s finding that drug reference texts are the preferred information resource: Zehnder 
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found that pharmacists experience information deficits most frequently in pediatrics, 
alternative medicine, pregnancy and lactation indications, and therapy guidelines[73]. 
Researchers in Greece performed a survey of hospital pharmacists, and found that hospital 
pharmacists in Greece seek pharmaceutical information, specifically drug indications, storage, 
dosage, and prices. The authors suggest that efficient information resources intended to 
support hospital pharmacists could contribute to more efficient and safer healthcare[74].  
However, specific information about a drug and sources of information are not the only 
factors that influence how drug prescribers and pharmacists use medications. Other factors 
exist that affect the decision making process. To understand what factors contribute to 
medication prescribing decisions, Schumock et al. surveyed physicians, clinical pharmacists, and 
formulary committee members (Table 3)[75]. Participants rated drug-related, direct, and 
indirect factors that influence drug prescription decisions on a 6 point Likert scale. All 
participants rated safety, effectiveness, formulary status, and restrictions on prescribing as 
highly influential. Physicians rated drug samples availability and personal experience higher 
than other participants did, while clinical pharmacists and formulary committee members rated 
clinical pharmacist recommendations, prescribing guidelines, and cost higher than physicians 
did[75].  
Studies on information needs and drug decision making are helpful and informative 
about generic drug information needs of pharmacists and prescribers, but do not provide 
significant help in developing information resources for pharmacists that support 
pharmacogenomics. Pharmacogenomics considerations can impact, where appropriate, six 
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influential factors identified by Schumock that govern which drugs and dosages are chosen 
(Table 3). These include: drug safety and effectiveness, monitoring requirements, FDA 
indications, local guidelines and clinical pharmacist recommendations. Schumock et al. 
identified many more factors that influence prescribing decisions, such as cost and experience, 
but only six are related specifically to pharmacogenomics in that they would change if a 
medication has pharmacogenomics implications (Table 3). For instance, a medication could be 
less safe or effective for a patient who has a specific genotype, and guidelines for 
administration would change in that case. In contrast, a medication’s cost would remain the 
same regardless of the patient’s genotype. 
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Table 3: Factors that influence prescribing decisions (Schumock et al. 2004). Factors in gray have been identified by 
the author as possibly being affected by pharmacogenomics. 
20 
However, we cannot know for certain that these information needs and factors are 
accurate or appropriate when applied to pharmacogenomics without asking that question 
directly of pharmacists. Collectively, these studies demonstrate that pharmacists and physicians 
have pharmaceutical information needs, and information influences their prescribing and 
recommendation activities. Information resources geared specifically toward pharmacists can 
help the medication-related information needs not just of pharmacists, but of the other 
clinicians that they support, and can influence the prescribing decisions made by clinicians. The 
information needs will guide the information model of clinicians’ pharmacogenomics 
information needs, which will inform the development of an information resource to meet 
those needs. 
1.1.5 Current Methods of Presenting Medication Information 
Clinicians have access to medication information resources, but those resources often lack the 
ability to effectively communicate pharmacogenomics medication information to clinicians for 
decision support. For instance, Structured Product Labels (SPLs) are the FDA-approved 
medication information resource for clinicians and pharmacists[24], so clinicians gravitate to 
product labels for information due to that status. The FDA has also determined the structure of 
the product labels, with predictable sections that provide important information, aiding 
clinicians in navigating the information[76]. However, clinicians prefer tertiary sources that 
digest information in a more accessible way [71]. 
21 
Despite the FDA-approved status of the product label and the FDA’s attempts to make 
the information structured and accessible, problems remain in terms of accessibility and 
usability of the information by clinicians[77], particularly in pharmacogenomics information. 
The FDA’s “Table of Pharmacogenomic Biomarkers in Drug Labels”[21] links to specific product 
label sections, but it does not provide direct access to specific implications for clear and 
actionable advice. Variations in product labels complicate matters further: pharmacogenomics 
information may be found in different product label sections for different drugs. For example, 
pharmacogenomic information in the abacavir label is located in the boxed warning, 
contraindications, warnings and precautions, and patient counseling sections; comparable 
details for aripiprazole are found in the clinical pharmacology, and dosage and administration 
sections. Other drugs have extensive differences in the location of pharmacogenomics 
information, as illustrated in Table 4.  
Table 4: Differences among drugs in location of pharmacogenomics information in SPLs (based on FDA Table of 
Pharmacogenomic Biomarkers in Drug Labels[21]) 
Furthermore, the current interface for accessing this information from the FDA Table of 
Pharmacogenomic Biomarkers in Drug Labeling impedes the ability of users to easily access the 
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information in the label. The user has to navigate a minimum 5 webpages, knowing what the 
correct links are, to access the label itself, and then navigate the label to find the information. 
Figure 1 illustrates the navigation necessary to access the label from the main page of the FDA 
Table of Pharmacogenomics Biomarkers in Product Labeling.  
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Figure 1: FDA Table of Pharmacogenomic Biomarkers in Drug Labeling 
1.                                                              2. 
3.  4. 
5.
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The dispersal of the information within the product label and the variability of its 
location among drugs impede the acquisition and use of the information. The information is 
structured in that it is placed into FDA-mandated sections, but pharmacogenomics information 
is not conveyed in a predictable, consistent format, or in an easily-identified location. Using just 
the product label, a user cannot easily extract all of the pharmacogenomics-related 
information. Structured representation of this information within the SPL sections using a 
semantic model and structured and computable representation to identify information from 
the product label as referring to a specific pharmacogenomics-related concept will make it 
searchable, and thus more accessible and usable. A semantic model is a set of explicitly defined 
terms and relationships that represents the concepts or information it is describing. Clinicians 
feel ill-prepared about engaging with pharmacogenomics[58], possibly due to lack of awareness 
of pharmacogenomics resources or due to the fact that those resources do not adequately 
meet their information needs. The Pharmacogenomics Knowledgebase 
(www.pharmGKB.org)[78–83] is primarily used by researchers. It includes information about 
gene variants that influence drug response the scientific literature supporting the associations, 
dosing guidelines, variant information, and depictions of drug pathways, among other things. 
PharmGKB is not designed to assist in real-time dosage and prescription decisions. The 
pharmacogenomics information available in SPLs is abstracted and available on PharmGKB 
(Figure 2), but clinicians with whom we have spoken about it do not find it easily accessible or 
useful, nor do they necessarily view it as having regulatory authority in the same way as 
information clearly from the FDA does. 
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Figure 2: PharmGKB.org Drug Labels Information 
Pharmacogenomics education programs have been developed to bridge these gaps. The 
Pharmacogenomics Education Program (PharmGenEd) from the University of San Diego 
developed continuing education modules tailored to pharmacogenomics instruction[84] for 
pharmacists and other healthcare professionals. It is not intended to fulfill specific information 
1.      2. 
3. 4. 
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needs at the point of care, but rather to educate professionals about pharmacogenomics in 
general. The Genetics/Genomics Competency Center (www.g-2-c-2.com) developed by the 
National Human Genome Research Institute provides educational resources to genetic 
counselors, nurses, and physician assistants on genetic and genomic topics in health care. 
Development of a section specifically for pharmacists was released in 2014[85,86].  
Clinicians need both general education on the topic[87], and quick answers at the point 
of care[58]. PharmGenEd and G2C2 fill only one of these requirements: general education, not 
quick answers. Further training is certainly an important component of pharmacogenomics 
training, but an information resource that can be referenced at the point of care has the 
potential to complement formal pharmacogenomics training[50,88], but data shows that it 
does not work well. Attention from the informatics community in the form of user-centered 
tools built on structured information models has the potential to improve the way clinicians 
interact with this information, an important step in integrating pharmacogenomics knowledge 
into clinical care. To be effective, pharmacogenomics information labeling needs to be well 
aligned with user needs. If clinicians struggle to locate this information in the product label, 
they may struggle to make informed decisions about their patients’ care. Mismatches between 
the structure of product labels and clinician goals, the lack of clear indication where 
information can be found, and difficulties in navigating and interpreting the information may 
lead to difficulties in finding the right information.  
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1.1.6 Knowledge translation 
Difficulties in translation -- the process of synthesizing, disseminating, exchanging and applying 
knowledge to improve healthcare[89] – represent a significant barrier to the use of 
pharmacogenomics in clinical care. Medicine in general experiences challenges in knowledge 
translation: in the United States, only 55% of the care received by adults was recommended by 
guidelines[90]. The problem is multi-faceted: the sheer volume of research papers to read can 
overwhelm clinicians; decision-makers lack the skills to perform effective literature searching or 
appraise it critically; systematic reviews do not necessarily provide actionable 
recommendations; financial disincentives exist; and clinicians depend on experience over 
evidence[89,91,92]. In 2006, Graham et al. proposed a conceptual framework for knowledge 
translation, called the knowledge-to-action cycle[93]. This framework describes how knowledge 
is created, used, and adopted. Pharmacogenomics currently remains in the knowledge creation 
portion of the cycle, because the use of pharmacogenomic genotyping to inform medication 
prescribing is not widespread at this time. Knowledge inquiry occurs as bench researchers 
identify more pharmacogenomic variants. This knowledge is synthesized into reviews, 
guidelines, and recommendations.  
The Knowledge to Action Cycle illustrates how pharmacogenomics relates to influences 
on physician prescribing decisions, and how an effective knowledge tool can move 
pharmacogenomics information from the knowledge creation portion of the cycle to the action 
portion[93]. First, health system changes must occur, such as genotyping, testing results and 
relevant patient data available in the EMR, and reimbursement[61]. Once that is in place, local 
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guidelines and information resources can encourage the use of pharmacogenomics in clinical 
practice (Figure 3).  
Informaticians, health systems, and clinicians must develop resources that effectively 
synthesize and communicate actionable recommendations to clinicians to move 
pharmacogenomics knowledge into the action cycle and apply it to care. Pathman et al. 
Figure 3: Preliminary model of how a pharmacogenomics information resource has the potential to 
integrate pharmacogenomics knowledge into clinical practice. (1Graham et al. 2006, 2Cabana et al. 1999, 
3Schumock et al. 2004, 4Pathman et al. 1996, 5Shuldiner et al. 
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developed a framework describing physician adoption and use of guidelines: physicians need to 
be aware of guidelines, agree with them, adopt them, and adhere to them consistently in order 
for guidelines to be effectively used[94]. Cabana et al. performed a systematic review to 
augment Pathman’s framework with a behavior change sequence and factors that influence 
each step[95]. Physicians require knowledge first, which includes familiarity and awareness of 
the information. In the case of pharmacogenomics, the knowledge includes the 
pharmacogenomics-related factors identified by Schumock as influential on prescribing: safety, 
effectiveness, monitoring requirements, FDA indications, local guidelines, and clinical 
pharmacist recommendations[75]. Then, they must adopt attitudes (agreement, self-efficacy, 
and motivation) that spur behavior changes: adoption and adherence. More simply, knowledge 
changes action. This model fits well into the first two constructs of the Unified Theory of 
Acceptance and Use of Technology, which posits four constructs of how technology is 
incorporated into users’ workflow: 1) performance expectancy; 2) effort expectancy; 3) social 
influence; and 4) facilitating conditions[96]. When users’ expectations of usability and 
functionality are met (constructs 1 and 2), they are more likely to use the technology and 
possibly change their behavior as a result. A pharmacogenomics resource has the potential to 
provide the knowledge to change attitudes and behavior, moving pharmacogenomics 
knowledge into clinical practice. 
We propose to design, develop implement, and evaluate a knowledge resource - 
PGx@Pitt - which moves pharmacogenomics knowledge into action. A resource that distills this 
information in a usable way, with a semantic model to make the information searchable and 
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linked, to clinicians at the point of care might influence prescribing behavior in a positive way, 
and bring pharmacogenomics knowledge into clinical decision making. 
1.1.7 Usability and User-centered Design in Pharmacogenomics 
Usability measures how well a resource performs the function for which it was designed[97]. 
Improved usability is one potential solution to the problem of poorly structured and presented 
pharmacogenomics information. Nielsen identified five facets of usability: learnability, 
efficiency, memorability, errors, and satisfaction[97]. A new user of a resource should learn 
how to use it quickly, be able to be highly productive using the resource quickly, remember 
how to use the resource easily, not experience many errors, and be subjectively pleased with 
the experience. Optimizing usability factors during design will make it more usable and able to 
fill the need the developers sought to address. 
Experience has shown the crucial importance of showing the right information in the 
right way, particularly in clinical information resources[65]. A computerized information 
resource in healthcare that fails at presenting information well can increase the risk of mistakes 
and adverse events. Studies of drug alerting systems illustrate the importance of presenting 
information appropriately[98–102]: it must be presented in a way that catches clinicians’ 
attention, clearly depicts the vital information, and suggests a reasonable course of action. This 
is particularly the case regarding new, unfamiliar, and rapidly changing pharmacogenomics 
information. 
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Furthermore, merely displaying the information in the optimal user interface is 
insufficient. Resource developers must use user-centered design principles that keep the user’s 
needs, abilities, expectations, and workflows in mind. The information that fulfills the user’s 
information need is key: in order to meet information needs, one must understand the role of 
information in the user’s work[103]. This requires the application of qualitative research, with 
its mixed methods of observations, interviews, free-flowing discussions, and workflow 
modeling, to understand the information needs that exist and how to design more effective 
information resources[103]. Clinicians’ work processes and thought models when they work 
with medications with pharmacogenomics implications must be understood to design highly 
usable pharmacogenomics information resources. Then, as it is being designed and 
implemented, the resource must be evaluated thoroughly to assure that it does not violate any 
of the usability requirements, and that it is providing the pharmacogenomics knowledge that 
clinicians seek. Our goal is to understand clinician information needs, design a resource that 
meets them effectively, and evaluate the resource to ensure that it does, to produce a user-
centered, clinical pharmacogenomics information resource, which clinicians do not currently 
have. That resource is PGx@Pitt. 
1.2 RESEARCH QUESTIONS 
1. Is it feasible to build a prototype pharmacogenomics information resource based on 
annotated pharmacogenomics statements from product labels?  
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2. What are the information needs and resource requirements of pharmacists regarding
pharmacogenomics information?
3. How does our pharmacogenomics information resource compare to available alternatives in
terms of perceived usability and functionality (task completion time and task correctness)?
1.3 DISSERTATION OVERVIEW 
Figure 4: Dissertation Overview 
Figure 4 provides an overview of the dissertation, consisting of 3 aims: 
• Aim 1: To build a semantic model and preliminary prototype.
o Develop a semantic model that describes the types of information available
about pharmacogenomics and how it relates to other information.
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o Write use cases to describe how the pharmacogenomics information resource
will support information seeking behavior.
o Annotate the pharmacogenomics statements in product labels and make them
linked and searchable using the semantic model to build a searchable,
computable graph of pharmacogenomics statements in product labels.
o Develop a prototype pharmacogenomics information resource (PGx@Pitt v. 1.0)
• Aim 2: To re-design a pharmacogenomics information resource through qualitative
inquiry.
o Identify pharmacists’ relevant pharmacogenomics information needs and
resource requirements using qualitative inquiries and observations.
o Refine use cases into user persona and use case scenarios based on the
qualitative inquiries and observations.
o Re-design the pharmacogenomic information resource interface to develop
PGx@Pitt v. 2.0 based on pharmacists’ information needs and resource
requirements.
• Aim 3: To evaluate the performance of pharmacogenomics information resource.
o Evaluate PGx@Pitt v. 2.0 using lab-based usability evaluations with pharmacists
to determine if user-centered re-design improved the pharmacogenomics
information resource usability compared to alternatives (PGx@Pitt version 1.0,
PharmGKB.org, and the FDA Table of Pharmacogenomic Biomarkers in Drug
Labeling).
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2.0  AIM 1: SEMANTIC MODEL AND PRELIMINARY PROTOTYPE DEVELOPMENT 
2.1 METHODS 
2.1.1 Use Case Development 
To inform the design of the semantic model, we worked with two pharmacists (a clinical 
pharmacist with pharmacogenomics expertise and a drug information specialist) to develop five 
use cases representing pharmacogenomics information needs.  
2.1.2 Semantic Model Development 
Efficient retrieval of the pharmacogenomics information available in product labels requires 
that information to be structured. Our research group used the use cases described above to 
guide the development of the first semantic model of clinical pharmacogenomics statements. 
We chose to structure the information with a semantic model because it supports knowledge 
integration with other resources and enables querying [104–110]. We developed a semantic 
model that would contain enough detail to meet the needs of those use cases. That work 
produced an RDF representation of annotated pharmacogenomics statements. 
36 
2.1.3 Semantic annotation of pharmacogenomics statements from product labels 
We finished annotations of pharmacogenomics statements in product labels using the semantic 
model developed in 2.1.2. The pharmacists used a Domeo plug-in[111] instead of Protégé 
Knowtator[112] to complete this set of annotations. Domeo is a web-based annotation tool 
which provided a more robust annotation environment for the purposes of this project. We 
chose to annotate labels for drugs for which recommendations have been rated “strong” by 
CPIC. 
2.1.4 Interface Prototype Development 
As a proof of concept, we developed a preliminary prototype interface using a subset of the 
annotations developed by the pharmacists. The prototype attempts to fulfill the information 
needs identified in the use cases.  
2.2 RESULTS 
2.2.1 Use cases 
The use cases (Appendix A) cover a range of circumstances, such as the pharmacogenomic 
genes that may impact a drug, the implication of gene test results, interpretation of gene 
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variants, treatment recommendations, testing recommendations, and the other drugs that are 
affected by a genotype. These use cases also account for other factors that influence the 
interpretation of pharmacogenomics impact, such as pharmacokinetic or pharmacodynamic 
impact, ethnicity, other medical statuses such as lactation, and risk from concomitant 
medications. We wanted to identify the types of information clinicians might seek to answer 
their questions. 
2.2.2 Semantic Model 
The semantic model contains three parts to describe a pharmacogenomics statement: 
the subject, or what is described; the object, or what is referred to; and the recommendation, 
or what action is specified by the statement (Figure 5). However, not all of the statements have 
all three information elements. For instance, not all pharmacogenomics statements contain a 
recommendation.  
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Figure 5: Three parts of the semantic model with preliminary ontology mappings. A) What is described, B) what 
is referred to, and C) what action is specified. SIO: Semantic science Integrated Ontology. IAO: Information 
Artifact Ontology (Boyce et al. 2013) 
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2.2.3 Semantic annotation of pharmacogenomics statements from product labels 
Five pharmacists associated with UPMC and the University of Pittsburgh used the semantic 
model to annotate 162 pharmacogenomics-related statements in 10 SPLs (abacavir, 
aripiprazole, azathioprine, carbamazepine, citalopram, clopidogrel, codeine, letrozole, 
tamoxifen, warfarin), which is a fraction of the total number of SPLs that require annotation. 
They used Protégé Knowtator[112] to create the annotations. We demonstrated the feasibility 
of turning product labels into actionable, semantically clear, linked data[105]. This knowledge 
representation approach moves towards clearly expressed semantics of the pharmacogenomics 
statements, which is necessary to quickly and effectively present the relevant 
pharmacogenomics information to clinicians in an information resource. 
2.2.4 Interface Prototype 
The main page of the prototype (Figure 6) is intended reflect the presentation of the 
same information available in the FDA’s Table of Pharmacogenomic Biomarkers in Drug Labels 
(Figure 4). We chose to represent the information in the same format as the FDA table because 
we wanted the information and structure of the information to be familiar to pharmacists who 
have previously used it. Familiarity and trustworthiness of the source of information are 
important factors in acceptance of information by clinicians[95], so we preserved that structure 
in our prototype interface.  
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Figure 6: Preliminary PGx@Pitt Interface Main Page 
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Figure 7: Preliminary PGx@Pitt Prototype Drug Page 
When the user selects the drug name, the complete drug information page is displayed 
(Figure 7). This is an improvement on the FDA Table of Pharmacogenomic Biomarkers in Drug 
Labels because it directs the user to the information, rather than listing only the source of the 
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information. The top table provides information about the gene variants, the phenotype, and 
whether the impact is on the drug’s efficacy or toxicity. This answers the basic questions about 
what variants impact drug response. Below that is a simplified pathway diagram illustrating 
how the drug interacts with and is metabolized by the gene(s) to produce the drug’s effect. This 
explains graphically how these genes interact with the drug, and why a variant has the impact it 
does on drug metabolism. At the bottom of the page are tabs containing pharmacogenomics 
information from the annotated SPLs, which answer his questions about what the gene test 
results mean, and FDA recommendations regarding how to change his patient’s treatment. 
Warfarin’s product label contains pharmacogenomics information in the Dosage and 
Administration, Clinical Pharmacology, and Warnings and Precautions sections. A different drug 
will have pharmacogenomics information in different sections. The effects tab contains 
information about the pharmacogenomics pharmacokinetic and/or pharmacodynamic effects. 
The Recommendations tab contains treatment or testing recommendations related to 
pharmacogenomics. All the information in these sections was taken from the structured RDF 
annotations described above. We presented it in a tabular format to make it more easily 
accessible: the concise organization of the knowledge is easy to scan and obtain quick, 
actionable information. Users can read about the drug’s pharmacogenomics-related 
pharmacokinetic or pharmacodynamic effects and recommendations without having to sift 
through text to find them. 
This preliminary proof of concept demonstrated that we can retrieve and present 
clinically relevant pharmacogenomics information from SPLs. The interface will change as a 
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result of input from clinicians about their information needs and workflow constraints, and 
involving concepts from other presentations of medication information. 
2.3 DISCUSSION 
These drugs represent over half of drugs rated by CPIC as having a strong recommendation for 
therapeutic action. Though the resource is incomplete in terms of information, we completed a 
significant number of annotations for drugs with major pharmacogenomic implications. This 
allows us to evaluate the interface and usefulness of the resource on many clinically relevant, 
high impact questions as we work to finish the semantic annotations of all 130+ drugs identified 
by the FDA as having pharmacogenomics implications.  
2.4 LIMITATIONS 
We were unable to complete all 130+ annotations due to the significant investment of 
resources and pharmacists’ time required. This was not feasible during the timeframe of this 
dissertation work. Future work will be focused on completing all the drugs identified by the FDA 
as having pharmacogenomics implications, as well as maintaining the resource as new drugs are 
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added to the FDA’s list. We also worked with a small group of local pharmacists to complete the 
annotation, and do not claim that the consensus annotations represent the consensus of all 
pharmacists regarding pharmacogenomics.  
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3.0  AIM 2: QUALITATIVE INQUIRIES INFORMED REDESIGN 
3.1 AIM 2.I: QUALITATIVE INQUIRIES TO USER NEEDS AND RESOURCE REQUIREMENTS 
3.1.1 Materials and Methods 
To better understand pharmacists’ information needs and resource requirements, I conducted 
qualitative inquiries, consisting of semi-structured interviews and observations of pharmacists 
in their work environment. I used a semi-structured approach to elicit a wide range of 
pharmacist perceptions about information seeking both for general prescribing and specifically 
with respect to pharmacogenomics. I also presented an early prototype (PGx@Pitt 1.0) to the 
users for feedback. We developed an interview guide (Appendix B) as a team based on 
information needs research strategies[113,114]. Each interview lasted approximately 45 
minutes and was audio recorded, with permission from participants. The study was approved 
by the University of Pittsburgh Institutional Review Board (IRB). 
I recruited 14 pharmacists through professional connections of the team using a 
convenience sampling strategy[114] designed to represent the diversity of needs and 
46 
perspectives associated with different care contexts including tertiary care centers, community 
practice, and private nursing home consulting pharmacy. I recruited until we reached saturation 
in the interviews and determined that no new concepts were being mentioned by participants. 
Interviews took place from December 2013-August 2014, and were conducted in the 
participant’s place of employment. 
3.1.2 Data analysis 
Audio recordings of interviews were transcribed verbatim before being analyzed using 
descriptive coding[114,115]. We developed a codebook (Appendix C) with a preliminary 
structure answering four basic questions, in general and specific to pharmacogenomics:  
1. What information needs do pharmacists experience while managing drug decisions?
2. What resources do they use to find drug information and why do they use them?
3. What do they like and dislike about them?
4. What tasks do they complete in a typical day related to drug decisions?
We coded using a structural approach: we developed conceptual phrases a priori that
represent ideas from the research questions, then applied them to the interview transcripts, 
adding codes throughout the process within the structure of codes (described above) as 
necessary to more finely represent the participants’ responses[115]. This analysis was intended 
to identify themes and sub-themes regarding information seeking behavior and perceptions of 
information resources in general and regarding pharmacogenomics. After coding was 
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completed, we grouped them into similar categories and assigned theme terms that connected 
them as a group of repeated, similar ideas[115]. Codes were assigned to sections of text and 
organized using QSR NVivo™.  
Two analysts coded seven of the transcripts independently to identify information need 
themes related to pharmacogenomics and to revise the emerging codebook accordingly. They 
discussed the differences to resolve disagreements and achieve consensus on codes that were 
used for the remainder of the transcripts. The number of subjects who mentioned each code 
was counted for descriptive purposes.  
3.1.3 Results 
Fourteen pharmacists participated. Table 5 describes their demographic information. 
Participants varied in length and type of experience (students, residents, and clinical 
pharmacists), and distribution of work contexts, including hospital, ambulatory care, nursing 
homes, and retail pharmacy.  
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Table 5: Demographics 
3.1.3.1 Pharmacogenomics in Practice 
All of the pharmacists had encountered pharmacogenomics through seminars, continuing 
education, or reading. None of the participants reported current use of pharmacogenomics 
information in practice. None had previously recommended genomic testing or personally 
managed a patient who had undergone pharmacogenomics testing. However, all anticipated 
that pharmacogenomics will have a growing impact on their practice in the near future by 
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assisting them in making informed recommendations that improve quality of care and health 
outcomes. 
3.1.3.2 Pharmacogenomics Information Needs 
Analysis of the interview transcripts led to the identification of 36 information needs that are 
directly or indirectly related to pharmacogenomics. Table 6 contains general information needs 
that can apply to pharmacogenomics. Table 7 contains information needs specific to 
pharmacogenomics. Other identified information needs not directly related to 
pharmacogenomics include general prescribing information such as cost, intravenous stability, 
and additive information, among others. The full list of information needs is available as 
supplementary material (Appendix C). The information needs were grouped in to four 
categories: background information, patient-specific information, medication information, and 
guidance information.  
Participants indicated that they find information in a variety of places, including books, 
journals, primary literature databases such as PubMed, resources provided by or mandated by 
the FDA, such as product labels and DailyMed, professional societies, drug companies, 
electronic health records, internal information resources at their place of employment, 
patients, search engines such as Google, the Centers for Disease Control and Prevention, and 
Medwatch. They also use tertiary resources, including the following frequently mentioned: 
Clinical Pharmacology, Dynamed, Facts and Comparisons, GlobalRPH, Hippocrates, Lexicomp, 
Micromedex, RXpertise, and UpToDate. The complete list is available in Appendix C. 
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Table 6: General Information Needs Related to Pharmacogenomics 
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Table 7: Pharmacogenomics-specific Information Needs 
3.1.3.3 Pharmacogenomics Resource Requirements 
Pharmacists identified what they perceived to be strengths and weaknesses of information 
resources and information. We identified three major themes that these traits fit into: the 
structure of the resource, pharmacists’ perception of the resource, and characteristics of the 
information provided in the resource. These traits are defined and summarized in Table 8.  
52 
Table 8: Pharmacists' Resource Requirements 
The pharmacists had strong feelings about the resources they prefer to use. They all 
discussed using multiple resources depending on the situation, including tertiary resources (e.g. 
Lexicomp™, Up-To-Date™, and Micromedex™), primary literature, the FDA, and even drug 
companies. Eleven out of 14 pharmacists mentioned using the FDA product labels. While they 
all trust the information provided by the labels, it was not usually their first choice. 
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Interestingly, many stated that they dislike seeking information in the product label because 
“the hard part about the label is you end up having to go to multiple sections to find 
information.” (Pharmacist 2). She prefers to start in a tertiary source, see what they say, then 
check the label itself to confirm, and then to be sure, she goes to the literature: “I like to 
confirm everything a couple places and sometimes the labels are a little behind the actual 
evidence. So I would probably take this information, go to the literature to see if I could confirm 
that.” Pharmacist 9 has a similar workflow: she finds answers and then confirms them with the 
product label, because “not that there’s bias, or potentially wrong information, but getting it 
from the source is better than…more accurate, generally, is what I would say.” 
3.2 AIM 2.II: USER PERSONA AND USE CASE SCENARIOS 
3.2.1 Materials and Methods 
We used the results of the qualitative inquiries to develop a use case persona of a composite 
pharmacist and use case scenarios. The persona was written by the authors as a composite of 
the characteristics discussed and observed during the qualitative inquiries. The user scenarios 
describe the likely use cases, information needs, and workflows of pharmacists who will engage 
with pharmacogenomics information.  
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3.2.2 Results 
The following persona (Table 9) is a composite of the pharmacists who participated in the 
interviews, with results of the interviews informing descriptions of values and goals. 
Table 9: User Persona 
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The following use case scenarios (Tables 10 and 11) describe situations where a pharmacist 
encounters a question about pharmacogenomics and needs to make a decision about how to 
find information, use information, and make a decision based on the information.  
Table 10: Use Case 1: General Pharmacogenomics Question During Hospital Rounds 
Table 11: Use Case 2: Clinical Decision Based on Patient Genotype 
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3.3 AIM 2.III: PGX@PITT REDESIGN 
Using the information needs, resource requirements, and information models identified and 
developed in Aims 2.i and 2.ii as guides, we iteratively re-designed the prototype interface to 
better meet pharmacists’ needs and support their information seeking behavior when 
managing medications with pharmacogenomics implications.  
3.3.1 Materials and Methods 
We used web development tool web2py[116] to develop and extend the existing prototype 
tool. Web2py is an open source web framework that uses Python to develop secure, database-
driven web applications. It has a model-view-controller web framework. It can interact with 
SPARQL to query a triple store to access the RDF representation of the annotated 
pharmacogenomics statements. 
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Using the information needs, resource requirements, and information models identified 
and developed in previous work, we re-designed the prototype interface to better meet 
pharmacists’ needs and support their information seeking behavior when managing 
medications with pharmacogenomics implications. Specifically, we reorganized the information 
available in the resource to minimize the time spent searching for answers to the most 
pertinent questions pharmacists have. We also redesigned graphical pathways illustrating the 
relationship between the drug, genotype(s), phenotype(s), and FDA recommendations. We 
presented the iterative interface changes to five pharmacists and pharmacy students 3 times 
throughout the design process for feedback. 
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3.3.2 Results 
3.3.2.1 Design Changes 
Figure 8: PGx@Pitt v. 1.0, Main Page 
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Figure 9: Drug page of PGx@Pitt v. 1.0 
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Figure 10: Expanded FDA Label Annotations Section of PGx@Pitt v. 1.0 
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Figure 11: Expanded Recommendations Section of PGx@Pitt v. 1.0 
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The first version of the prototype was designed to provide information on the following: 
the change in efficacy or toxicity as a result of a particular gene variant (Genes and Variants, 
Figure 9); a simple pathway illustrating the relationship between the gene variant and the drug 
(Pathways, Figure 9); and the annotated statements from the product label in an accordion-
style interface (Figures 10 and 11), organized by product label section, pharmacokinetic and 
pharmacodynamic effects, and recommendations (such as dose or testing recommendations). 
These prototype design decisions were made based on the recommendation of a two 
pharmacists, to provide a simple interface for potential users to use and provide feedback.  
Table 12: Usability Observations and Design Changes 
The pharmacists were generally receptive to the information provided by the first 
version of the pharmacogenomics resource during the qualitative inquiries. However, they 
experienced some difficulty related to usability and understanding the information presented 
to them. We organized these problems into three categories (Table 12): Layout, Information 
Display, and Information. The layout was problematic because the accordion design of section 
containing the information from the product label seemed almost invisible. They also did not 
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notice the Drug Info Links table. As a result, many of the pharmacists were unable to access in 
the product label information, and they requested links to other sources despite those links 
being available. While they liked the illustration of the interaction between the drug and the 
gene, they were often confused by the table containing information about efficacy and toxicity, 
or how that influenced the phenotype. They were also confused by the notation of the gene 
variants (“star” notation), and they wanted a clear recommendation. Finally, they were 
concerned about the source of the information. It was not clear to them that all the statements 
originated from the FDA-approved product labels. They also wanted more background 
information in general about pharmacogenomics, and specifically about the drugs and genes to 
understand the information presented to them.  
3.3.2.2 Re-designed Interface: PGx@Pitt v. 2.0 
We made very few changes to the main page, except we streamlined the table (Figure 12). We 
re-designed the pathway portion of the drug page by combining the table at the top of the page 
(Figure 9) with the graphical pathway. This ultimately became a table with visual aspects (Figure 
13), leading the user from the interaction between the drug and the variant, to information 
about the phenotype, and finally to the FDA recommendation. We reorganized the tabs so the 
most relevant information is presented first: Boxed Warning, and recommendations related to 
the drug selection, dosage, and genetic testing, if relevant. Then all the other information was 
provided on the second tab, organized by product label section (Figure 14). Our goal was to 
focus their attention to the product label information with the most relevant information first, 
then allow them to explore the rest of the label information on the second tab while making it 
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clear that it all came from the product label. We also made the links to other resources more 
visible, including a link to the exact product label used for the annotation.  
Figure 12: PGx@Pitt v. 2.0, Main Page 
Sortable columns 
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Figure 13: PGx@Pitt v. 2.0, Drug Page 
Figure 14: PGx@Pitt v. 2.0, Product Label Annotations section 
New visualization 
Improved links Summary 
tab 
All sections 
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3.4 DISCUSSION 
To our knowledge, this is the first study to explicitly identify pharmacogenomics-related 
information needs of pharmacists, and to discuss these needs in the context of preferences and 
requirements regarding pharmacy information resources. We sought to understand the 
pharmacogenomics-specific and general information needs of pharmacists, and how they 
would incorporate pharmacogenomics information into their practice. We used qualitative 
inquiries to elicit information needs and information resource requirements of pharmacists 
when engaged with pharmacogenomics information. The novel findings of this study include a 
list of general and pharmacogenomics-specific information needs, and a related list of 
requirements for information sources. We also re-designed the interface of our 
pharmacogenomics information resource based on the results of the qualitative inquiries. In 
particular, we developed a novel way of presenting the complex information that comprises 
pharmacogenomics information: drug, gene, variant, phenotype, and recommendation 
information. The generic presentation is shown in Figure 15.  
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Figure 15: Generic Model Presentation of Pharmacogenomics Information 
Participating pharmacists’ information needs, both generally and specifically for 
pharmacogenomics, fall into four categories: background, medication, patient-specific, and 
guidance-related information. These needs are similar to those of physicians, particularly with 
respect to the interpretation of test results, recommendations for alternatives, prevalence in 
various ethnic groups, and genotypic testing information[7,8]. We found specific information 
needs directly and indirectly related to pharmacogenomics that were not identified in similar 
studies of physicians pharmacogenomics knowledge gaps[7] and the usability of 
pharmacogenomics decision support aids[8]. These include monitoring information, severity of 
risk, and other drugs affected by a biomarker. Table 13 shows the themes identified in this work 
compared to themes identified in other work.  
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Table 13: Pharmacogenomics Information 
Pharmacists in this study prefer resources that are peer-reviewed, online, full-text, 
referenced, with visualizations and links to other sources (Structure of the Resource). They 
perceive high quality resources to be familiar, trustworthy, up-to-date, and well organized 
(Perceptions of the Resource). Finally, they perceive high quality information to be quick, 
concise but thorough, relevant, accurate, and easy to use (Perceptions of the Information). In 
particular, they are very concerned with the provenance of the information: they want 
references, access to full-text studies, and prefer information that comes from FDA-mandated 
product labels. If they are unsure of the provenance, they prefer to rely solely on what the 
product label states. 
69 
3.5 LIMITATIONS 
Alternative approaches (focus groups, surveys, embedded observation) exist that could have 
been used to address these questions and may have found different results. None of the 
participants had had prior knowledge of the information resource. Coder bias in analysis and 
interpretation can be a limitation of studies of this type. To address this bias, the transcripts 
were reviewed and coded with 50% overlap by two researchers. Discrepancies in agreement 
were discussed by the coders and brought to consensus. In addition, we validated the results 
with member checks with pharmacists. It is possible that the unfamiliarity of participants with 
pharmacogenomics is a limitation, but it is an accurate reflection of the current state of the 
practice. While the study provides a detailed description of pharmacists’ information seeking 
behavior and information needs, the results may not be generalizable to all pharmacists or all 
clinicians in other settings. The participant clinician types were slightly skewed towards nursing 
home consultant pharmacists. That group has had the least exposure to pharmacogenomics. 
While their feedback was very helpful, we decided to write the user persona to reflect a 
hospital-based pharmacist rather than a community or nursing home based pharmacist, 
because we anticipate that hospital pharmacists will encounter pharmacogenomics before 
other environments. The study is limited by the small sample size, but we found a priori that 
the study was sufficiently powered with only 12 participants based on the time measurement in 
seconds. We sought 16 so we could have even distribution of the 8 questions across all 4 
resources.  
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4.0  AIM 3: EVALUATION 
4.1 MOTIVATION 
Researchers have established the feasibility of incorporating genomic information into 
EMRs[117], and we know that interpreting this information clinically at the point of care is 
difficult[7,22,54,118]. Little work has been performed focusing on the display and 
interpretation of genomic pharmacogenomic information in the context of medication 
prescription.  
4.2 AIM 3: CONDUCT USABILITY STUDIES TO EVALUATE THE TOOL AND INFORM 
POTENTIAL IMPROVEMENTS.  
I conducted laboratory-based usability studies, specifically, empirical comparisons of 
simulated decisions[119]. Pharmacists and pharmacy students were asked to find 
pharmacogenomics information available in FDA-approved product labels to answer specific 
questions using the redesigned version of PGx@Pitt (version 2.0), the previous version of 
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PGx@Pitt (version 1.0), the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling, and 
the FDA labeling information in PharmGKB.  
Measurements included: time to answer the question; correctness of the answer; and 
the user’s subjective satisfaction with the information found and the resources used. Task 
correctness was measured as whether or not the subjects found the information they were 
asked to find, as determined by the researchers. Subjective satisfaction was measured using the 
System Usability Scale[120]. 
We hypothesized that PGx@Pitt version 2.0 would perform better than the other three 
resources on average time to answer questions, rate of finding a correct answer, and the user’s 
subjective satisfaction with the information and resources. Further, we hypothesized that 
PGx@Pitt version 2.0 would outperform the other three resources particularly well on the 
multi-drug tasks. 
4.2.1 Materials and Methods 
Pharmacists and pharmacy students were asked to find pharmacogenomics information 
available in FDA-approved product labels to answer specific questions using the first version of 
the pharmacogenomics information resource (PGx@Pitt 1.0), the redesigned version (PGx@Pitt 
2.0), the FDA Table of Pharmacogenomic Biomarkers in Drug Labeling 
(http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.ht
m), and the FDA labeling information in PharmGKB (https://www.pharmgkb.org/view/drug-
labels.do). We recruited pharmacists through professional connections of the authors using a 
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convenience sampling strategy[23] designed to represent the diversity of needs and 
perspectives associated with different care contexts including tertiary care centers, community 
practice, and private nursing home consulting pharmacy. Evaluations took place during July and 
August 2015, and were conducted in the participant’s place of employment. 
I developed 8 pharmacogenomics information tasks that could be answered on all 4 
information resources: PGx@Pitt version 1.0, PGx@Pitt version 2.0, the FDA Table of 
Pharmacogenomic Biomarkers in Drug Labeling, and the FDA label pharmacogenomics 
information in the PharmGKB. The tasks are listed in Table 14. Four of the tasks are single drug 
questions, and four are multi-drug questions. The tasks were developed with the help of a 
professor of pharmacy with pharmacogenomics expertise. They are all able to be answered 
correctly using each resource. They cover a range of pharmacogenomics concepts that have 
been identified as important pharmacogenomics competencies for pharmacists by the 
American Society of Health System Pharmacists (ASHP) and the Pharmacogenomics Education 
Program at UC San Diego (PharmGenEd)[84].  
The task order and the order of the resources were varied among participants to avoid 
order effects using a pseudo randomization technique. The order of tasks was randomly 
assigned to the first participant, and the order of tasks were assigned to each subsequent 
participant based on that first participant, to ensure that each task was performed on each 
resource an equal number of times. The order of resources was assigned randomly to each 
participant.  
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The resources were available locally, to guarantee that access would not be dependent 
on internet connectivity. We used HTTrack Website Copier[121] to download the FDA Table of 
Pharmacogenomic Biomarkers in Drug Labeling (downloaded June 2, 2015) and the FDA Drug 
Labeling portion of PharmGKB.org (downloaded June 5, 2015).  
The pharmacists were instructed to only use the assigned resource for each task, and 
not to seek the information on any other sites. I recorded the pharmacists’ activity on the 
screen and their voices simultaneously using SnagIt, a Chrome web browser extension, for 
screen capture[122]. The participants were instructed to highlight the text of the answer to 
each task on the screen when they found it. Each task had a maximum completion time of 10 
minutes. Tasks that were not completed in this time were marked as incorrect. The task 
completion times for incorrect and incomplete tasks were measured as the time it took them to 
find the incorrect answer, give up, or reach 10 minutes. After all 8 tasks were finished, the 
participants completed the System Usability Score questionnaire[120], a validated assessment 
of perceived usability of systems and interfaces, for each resource. Measurements included: 
the time to complete each task from start to finish, as indicated by highlighting; the correctness 
of each answer as determined by the investigators; and the System Usability Score for each 
resource. 
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Table 14: Pharmacogenomics Evaluation Tasks 
4.2.2 Data Analysis 
Data was analyzed using MiniTab[123] and R[124]. Analysis included: descriptive statistics of 
demographic data of participants; regression to examine task completion time versus task 
number for order effect; the Kruskal-Wallis and Dunn test for post hoc pairwise correction to 
analyze the significance of task completion time comparing the four resources across all eight 
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tasks; a one-way ANOVA and Games-Howell test to analyze the significance of System Usability 
Scale scores of all four resources; and a Chi-square test of the correctness of answers for each 
resource, with a post-hoc pairwise comparison Bonferroni correction. p-values were considered 
significant at 0.05. We considered 3 types of incorrect answers: the user gave an answer that 
was wrong; the user failed to find an answer before 10 minutes; and the user gave up before 
finding an answer, but before the 10 minute mark. All of these are considered incorrect as they 
are a failure to find the correct answer. 
4.3 RESULTS 
16 pharmacists representing a variety of clinical practice environments with an experience 
range from 2 months to over 20 years participated in the usability evaluation. Most of the 
pharmacists were clinical pharmacists (9), and of those, a majority (5) was nursing home 
consultant pharmacists. Their demographic information is summarized in Table 15.  
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Table 15: Demographics 
4.3.1 Task Completion Time 
The various resources had significant differences in task completion times (Figure 16) (Kruskal-
Wallis, p = 0.001). Task completion time and order are not correlated (p = 0.08, r2 = 0.02). Task 
completion times all followed a lognormal distribution, requiring the use of Kruskal-Wallis 
instead of ANOVA. Search tasks were completed more quickly using PGx 2.0 resource compared 
to both the FDA table (Dunn, p = 0.003) and PharmGKB (Dunn, p = 0.0087), as well as using PGx 
1.0 compared to the FDA table (Dunn, p = 0.0473). All other pairs were not statistically 
significantly different.  
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Figure 16: Boxplot of Time (s) by Resource. The boxes and whiskers represent the median interquartile ranges. 
The asterisks represent outliers. The solid circles represent the mean task completion times. 
4.3.2 System Usability Scale Scores 
 Significant differences in SUS scores exist between the various resources (Figure 17) (ANOVA, p 
< 0.0005). The SUS score data are normally-distributed, allowing for use of ANOVA. The 
resources do not show equal variance so Games-Howell was used for post-hoc analysis. SUS 
scores were higher for PGx 2.0 than either the FDA table (Games-Howell, p = 0.001) or 
PharmGKB (Games-Howell, p = 0.013), as well as higher for PGx 1.0 than the FDA table (Games-
Howell, p = 0.01). All other pairs were not statistically significantly different.  
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Figure 17: Boxplot of System Usability Scales by Resource. The boxes and whiskers represent the median and 
interquartile ranges. The asterisks represent outliers. The solid circles represent the mean SUS scores. 
4.3.3 Task Correctness 
Of the different resources, on only one (PGx 2.0) did users find the correct answer 100% of the 
time (Table 16). A Chi-square test with a Bonferroni correction showed a difference among the 
resources in rate of task correctness (χ2(3,N=128)=13.393, p = 0.004). Pairwise Chi-square tests 
with a Bonferroni correction showed that PGx 2.0 performed statistically significantly better 
than all other resources (p = 0.006). Of the incorrect answers (total = 22), in 2 cases, the 
participants ran out of time (maximum = 10 minutes); in 6 cases, the participants gave up; and 
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in the remaining 14, they found an answer they believed to be correct, but it was not the 
correct answer. 
Table 16: Task Correctness Data 
4.4 DISCUSSION 
On task completion time and System Usability Scale scores, PGx@Pitt version 2.0 performed 
better than both PharmGKB annotated drug labels and the FDA Table of Pharmacogenomic 
Biomarkers in Drug Labeling. PGx@Pitt 2.0 performed better than the FDA Table on task 
correctness. PGx@Pitt 2.0 was the only resource on which users answered every question 
correctly. Also, PGx@Pitt version 1.0, designed prior to the qualitative inquiries with 
pharmacists, was only better than the FDA table, not PharmGKB, on task completion time and 
SUS scores. PGx 2.0 was not better than PGx 1.0 on any measures. Considering that the 
underlying data and data structure are identical, this is not surprising. However, the changes 
made based on the problems identified in the qualitative inquiries improved the web interface, 
boosting its usability higher compared to PharmGKB, as measured by task completion time and 
SUS scores. While it might appear that PGx 2.0 is not an improvement on PGx 1.0 if it is not 
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significantly better than 1.0 in any measures, the fact that PGx 2.0 performs significantly better 
than PharmGKB but PGx 1.0 does not is a notable achievement, as PharmGKB is the gold 
standard of pharmacogenomics information resources at this time. Furthermore, users were 
able to find the correct answers 100% of the time using PGx 2.0, but not with 1.0. This 
demonstrates that the improvements to PGx@Pitt made it measurably better than both the 
FDA and PharmGKB. 
Participants in both the qualitative inquiries and the evaluations indicated that while the 
information provided by PGx@Pitt was important, a stand-alone web interface would not be 
adequate for effectively using pharmacogenomics information clinically. Ideally, they would 
prefer a resource that is integrated into the electronic medical record and connects actual 
patient genotype data with FDA-approved drug label information. They also felt that the 
information provided by the FDA did not always give them a satisfactory recommendation on 
how to proceed with a specific patient. Recommending that a dose be lowered is not as helpful 
as recommending a specific dose; recommending that an alternative drug be given is not as 
helpful as recommending specific alternatives. The FDA hesitates to provide actual clinical 
recommendations, instead preferring to let clinicians draw their own conclusions from the 
information provided. The Clinical Pharmacogenetics Implementation Consortium (CPIC) 
develops clinical guidelines for pharmacogenomics variants that can help address that gap[46]. 
PharmGKB, it must be noted, offers CPIC guidelines where relevant. However, pharmacists do 
not necessarily recognize those guidelines as having regulatory authority the way FDA label 
information does, and may hesitate to use them.  
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Clinicians of all types struggle with pharmacogenomics information[14,58,30,59,60], and 
find it confusing. To make a decision, a clinician, either a physician or a pharmacist, has to 
incorporate information about a gene, how it interacts with a drug, what the phenotype of a 
given gene variant is, and the phenotype of that variant when the patient is given an affected 
drug[58]. Interpreting this information presents multiple challenges, including unfamiliar and 
potentially confusing notation for describing gene variants and phenotypes. Studies have 
shown that clinicians feel poorly informed about pharmacogenomics testing, and that they 
have a difficult time interpreting test results[14,30] and the complex interactions between 
drugs and genes[58].  
One possible solution to managing this overwhelming information is to identify the 
clinically relevant information and make it useful. This is what we have attempted in building 
PGx@Pitt: a simple, single page that does not aim to be comprehensive, but instead gives label 
information clearly and concisely, with a visualization to help explain the relationship between 
the gene variant(s), drug(s), and phenotype(s). We designed it with the help of pharmacists, 
who told us what information they value and how they want to use it. The results from our 
evaluation indicate that presenting pharmacogenomic information in this way makes it easier 
for clinicians to access it, understand it, and use it quickly when making drug decisions. We do 
not claim to have developed the best method of presenting this information to pharmacists in 
an effective way. More research into phenotypes, pharmacogenomics, and clinician decision 
making workflows is necessary to further improve clinical phenotype presentation.  
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Eleven sites in the Electronic Medical Records and Genomics (eMERGE) Network are 
implementing pharmacogenomics clinical decision support (CDS). A recent article found that 
while these sites have experienced delays and barriers in implementation of 
pharmacogenomics CDS, they are generally surmountable[48]. Another related study found 
that significant heterogeneity exists among sites in how genetic information is entered and 
stored[125]. Each institution enters and stores it differently, and each institution may enter it 
multiple different ways and display in multiple different areas of the EHR system. This variability 
poses a considerable barrier to interoperability to successfully share and display genetic 
information. The eMERGE group is working to develop an Infobutton that will author genomic 
medicine information to share with genetic testing results with clinicians within the eMERGE 
Network[126]. The eMERGE network is working toward this goal in parallel to our efforts, and 
we have come to the same conclusions about the need to incorporate genetic information into 
electronic health records. Trust-worthy, well-presented, clear pharmacogenomic information 
presented in a clinically useful way and combined with patient data and local or CPIC practice 
guidelines have the potential to move pharmacogenomics into clinical practice.  
4.4.1 Limitations 
Limitations include a small sample size, range of possible designs, and number of tasks. The 
results of this work cannot be generalized to other resources or domains, nor can we claim that 
any one of the interface changes definitely improved usability or performance. We cannot claim 
that the improved usability leads to improved pharmacogenomics-related outcomes. Clinical 
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implementation of genetic testing and genotype-guided clinical decision support is necessary to 
determine improved clinical outcomes.  
4.5 CONCLUSIONS AND FUTURE WORK 
As genotyping becomes less expensive and more common in clinical practice, clinicians of all 
types will need trustworthy, easily accessible information about pharmacogenomics to make 
informed decisions. Genetic variation is only one class of factors to consider when making a 
drug decision, but in the era of personalized medicine, knowing genotypes is a necessary step 
to tailor treatments to a patient. Our semantic model of pharmacogenomics information in 
product labels makes the information computable and searchable; the user-centered design 
methods make the information usable. The resulting resource is demonstrably more usable 
than alternative resources when locating clinically relevant pharmacogenomics information. 
The design and development of our pharmacogenomics resource is a necessary step toward 
integrating genetic information into drug decisions and personalizing medicine. The next step is 
finishing the annotations of the rest of the SPLs with pharmacogenomics information, and 
maintaining the information as it changes over time. 
The participating pharmacists told us repeatedly that a stand-alone web portal for 
pharmacogenomics information will be insufficient when attempting to integrate genetic 
information in decision making. The eMERGE network sites attempting to integrate 
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pharmacogenomic information into EHRs support this idea[125]. This information will need to 
be paired with genetic, medication, diagnosis, and co-morbidity information about a patient 
and provide tailored recommendations at the point of care to be clinically useful. That requires 
connecting the semantic model, product label statements, and interpretations to current 
electronic health records and computerized physician order entry systems. All of this depends 
on patients having genotype testing performed, which is not currently the standard practice. 
However, when that happens, our resource is ready to be integrated into current information 
systems to support clinical decision making. 
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5.0  FINAL CONCLUSIONS AND FUTURE WORK 
In this dissertation work, we have used qualitative methods to design, build, and evaluate a 
pharmacogenomics information resource that supports the use of genetic data in drug decision 
making by pharmacists better than alternatives. We demonstrated that the redesigned 
interface is more usable in terms of task completion time, correctness, and perceived usability 
than comparable alternatives. We were able to achieve the three aims we set out to achieve in 
section 1.3: 
• Aim 1: Semantic model and preliminary prototype development.
o We developed a semantic model that describes the types of information
available about pharmacogenomics and how it relates to other information.
o We wrote use cases to describe how the pharmacogenomics information
resource supports information seeking behavior.
o We annotated the pharmacogenomics statements in 10 SPLs.
o We developed a prototype pharmacogenomics information resource (PGx@Pitt
v. 1.0)
• Aim 2: Qualitative inquiries informed redesign.
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o  We identified 36 pharmacists’ relevant pharmacogenomics information needs in 
4 themes and resource requirements in 3 themes using qualitative inquiries and 
observations. 
o We refined use cases into a user persona and use case scenarios based on the 
qualitative inquiries and observations. 
o We re-designed the pharmacogenomic information resource interface to 
develop PGx@Pitt v. 2.0 based on pharmacists’ information needs and resource 
requirements. 
• Aim 3: Evaluation.  
o We evaluated PGx@Pitt v. 2.0 using lab-based usability evaluations with 
pharmacists and found it out-performed PharmGKB.org and the FDA Table of 
Pharmacogenomic Biomarkers in Drug Labeling in 3 measures: task completion 
time, perceived usability, and task correctness. 
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5.1 PHARMACOGENOMICS SEMANTIC MODEL AND ANNOTATED STATEMENTS PROVIDE 
THE UNDERLYING DATA FOUNDATION FOR PGX@PITT  
We built a prototype pharmacogenomics information resource, with a semantic model of 
pharmacogenomics information in product labels and annotated statements as the underlying 
data source. The completed annotations represent over half of drugs with major 
pharmacogenomics implications, per the FDA and CPIC. Though the resource is incomplete in 
terms of information, we completed a significant number of annotations for drugs with major 
pharmacogenomic implications. This allowed us to evaluate the interface and usefulness of the 
resource on many clinically relevant, high impact questions as we work to finish the semantic 
annotations of all 130+ drugs identified by the FDA as having pharmacogenomics implications.  
5.2 QUALITATIVE INQUIRIES INFORM PHARMACOGENOMICS INTERFACE DESIGN 
We conducted qualitative inquiries to identify information needs and resource requirements of 
pharmacists as they engage with pharmacogenomics information. We identified 36 information 
needs in 4 themes: background information, patient information, medication information, and 
guidance information. We identified 3 themes in pharmacists’ resource requirements: the 
structure of the resource, perceptions of the resource, and perceptions of the information. We 
then developed user personas and use case scenarios to illustrate pharmacists’ 
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pharmacogenomic information seeking behavior based on the information needs and resource 
requirements. We then re-designed the interface of the prototype information resource based 
on the results of the qualitative inquiries. As part of the redesign, we developed a novel way to 
present pharmacogenomics information to pharmacists.  
5.3 EVALUATION DEMONSTRATES PGX@PITT IS HIGHLY USABLE INFORMATION 
RESOURCE FOR PHARMACOGENOMICS DECISION MAKING 
We evaluated the usability of the pharmacogenomics information resource and demonstrated 
that demonstrated that user-centered, qualitative methods applied to biomedical informatics 
applications can improve the usability of the application. Specifically, we learned that the use of 
qualitative inquiries and iterative, user-centered design of a pharmacogenomics information 
resource improved the resource to the point that it is significantly superior to alternatives in 
task completion time, task correctness, and perceived usability by pharmacists.  
5.4 FUTURE WORK 
Knowledge translation, also known as implementation science, is a vast area of research that 
attempts to integrate evidence-based practice into standard care in a given setting[89]. This 
thesis work offers a significant step forward in moving pharmacogenomics information from 
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the knowledge to action portion of Graham’s Knowledge-to-Action Cycle[93,127]. We proposed 
to develop a resource that moved pharmacogenomics information into the action portion of 
that cycle. In Figure 18, we offer a more detailed view of the Knowledge Tools/Resources 
triangle in the Knowledge to Action cycle. 
Figure 18: Pharmacogenomics Knowledge Tool/Resource Factors and Information 
This thesis identifies the factors that influence pharmacists’ use of a pharmacogenomics 
information resource: the resource structure, the pharmacists’ perceptions of the resource, the 
pharmacists’ perceptions of the information, and finally, the information itself. We also 
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identified four categories of pharmacogenomics information that influence decision making: 
background information, medication information, guidance information, and patient 
information. Until pharmacogenomics knowledge is connected directly to patient information, 
particularly genetic testing results, it cannot be used clinically.  
Building pharmacogenomics resources that are connected to or part of electronic health 
records still requires a significant amount of work. A stand-alone, web-based resource as we 
have now would not be feasible, according to the comments made by the participating 
pharmacists in both the qualitative inquiries and evaluation. The information would need to be 
embedded in the EMR in some way, per their recommendations. Decisions would have to be 
made about whether to use on-demand, passive alerting, or more intrusive, active alerts that 
require justification for using a drug or a dose despite genetic information. The alerting field has 
well-documented challenges, most notably finding the balance between getting pertinent 
information to clinicians, and not overwhelming them with alerts and causing alert fatigue[128–
130]. For instance, drug interaction alerts are common in practice. They often are not useful 
because they lack adequate specificity and sensitivity, thus aggravating the prescriber with 
inappropriate alerts. One way of reducing this is by tiering alerts by severity: only the most 
severe and important alerts with sufficient evidence are shown to the prescriber; the rest are 
passive[101]. A similar approach could be applied to pharmacogenomics: some biomarkers 
have more impact on the patient than others, and alerts could be tiered accordingly. Otherwise, 
pharmacogenomics alerts could become just another in a long cascade of aggravating pop-ups 
that clinicians click through and ignore. Effectively implementing the use of patient genetic data 
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requires understanding how best to present it to clinicians in the context of the EMR, not just 
the information itself, as we did in this thesis work. 
Before pharmacogenomics can be adopted into standard practice, a number of 
substantial hurdles must be overcome: first, the comparable effectiveness and cost 
effectiveness of pharmacogenomics testing must be demonstrated. That is, we must 
demonstrate that pharmacogenomic testing can improve clinical outcomes compared to the 
standard of care, or not testing. We must also demonstrate that the cost of the testing is less in 
the aggregate than the cost of pharmacogenomics-related adverse events. Then, we must have 
sufficient Clinical Laboratory Improvements Amendment (CLIA) certified labs to process the 
genetic testing quickly and efficiently. Waiting weeks for genetic testing to inform a drug test is 
not effective. An even better process would be to perform pre-emptive pharmacogenomic 
testing: perform the test when the patient is well and not taking any drugs, so the information 
is available well in advance of the prescribing decision.  
Further issues exist not just in understanding how to present pharmacogenomics 
information, but also which information about which drugs and genotypes are significant 
enough to alert clinicians. For instance, evidence remains mixed and unclear about whether 
warfarin improves warfarin dosing, specifically by shortening the time to reach appropriate INR, 
and by reducing adverse events and unplanned hospitalizations[4,15,16,33]. Warfarin is a 
powerful drug that requires precise dosing to reach its narrow therapeutic window. Many 
factors affect the dose for a given patient, including weight, age, concomitant medications, and 
comorbid conditions. Genetic factors do influence the dose, but they are only one among many, 
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and may not affect the clinical outcomes as strongly as other drugs. For instance, the HIV drug 
abacavir is contraindicated for patients who carry the gene variant HLA-B*5701, because they 
are at high risk of experiencing a severe, life-threatening hypersensitivity reaction[131]. 
Clopidogrel has strong recommendations for genetic testing based on clinical evidence that 
poor metabolizers do not experience a therapeutic benefit from clopidogrel, and thus should be 
prescribed an alternative[132]. This might be a case where biomarkers for certain drugs ought 
to have an interruptive alert, but another biomarker for another drug should not. Identifying 
the drug-gene combinations that must be urgently alerted will require more research. 
Just as we do not know which biomarkers have the greatest impact on outcomes at this 
time, we also do not know what changes to our interface had the greatest impact on the 
usability. We did not change the information provided, but we did change how it was 
presented. More information is available in the new table of the drug pages, and the 
presentation of the pharmacogenomics statements from the product label has changed. The 
users appeared to interact with all parts of the interface, but for different purposes. They 
appeared to use the table that illustrates the relationship between the variant, the drug, and 
the phenotype for a general introduction to the drug in question, but then read through the 
FDA label annotations below to find the specific answers to the task questions. A more detailed 
usability analysis testing specific changes would be necessary to elicit which piece of the 
interface influenced the improved usability.  
One of the strengths of our resource compared to alternatives is a direct result of the 
use of the RDF graph and semantic model as the underlying data model. It allows users to query 
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the graph and answer questions that PharmGKB and the FDA Table cannot easily answer, such 
as “What drugs require genetic testing?” Our prototype demonstrates this by allowing users to 
query the resource in this way with pre-written SQL queries. In PGx@Pitt 2.0, users can sort the 
drugs by column, by drug name, therapeutic area, and biomarker. This allows users to easily 
answer questions such as, “What drugs are affected by CYP2C19?” to determine if other drugs 
the patient might be on are affected. However, at this time, the resource is drug-centric, rather 
than biomarker-centric. We offer detailed drug pages, but not biomarker pages. A future 
improvement to the resource is to add biomarker pages. The pages might include a 
visualization illustrating the biomarker itself and how it interacts with drugs, a list of all drugs 
that are affected by the biomarker, and links to those drug pages. This would allow users to 
answer more detailed questions about a given test result without having to go and look at each 
individual drug page, and better leverage the semantic model that supports these types of 
queries. Multi-drug information needs are significant, as many patients are on more than one 
drug, and will likely to be on more drugs over time as they age. Our prototype is already 
answering some of them well, but further development is necessary to answer them more 
completely. 
Product labels contain other information that remains difficult for clinicians to access 
and use effectively. The mandated structure of product labels has improved the standard form 
of the information and made it easier to find pertinent information. However, inconsistency 
remains in the location of some types of information, such as drug-drug interaction data. The 
FDA mandates that known and predicted drug-drug interaction information be provided in the 
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product label [76], but does not require a standard form for sharing it. For instance, drug-drug 
interaction information typically appears in Clinical Pharmacology and Drug Interactions 
sections, but occasionally can appear in Warnings and Precautions. Older drugs may provide 
the information as unstructured text, while newer drugs may provide it as a table. A table is 
more concise and easily searchable by a user, but typically contains less information about the 
clinical studies that produced the data than the unstructured text does. We think it would be 
highly beneficial for the FDA to require pharmaceutical companies to provide more structured 
information for the SPLs (e.g., as annotation like those we created in this project) rather than 
providing in the current unstructured text.  
Our success in annotating pharmacogenomics information in product labels using a 
semantic model to make it structured and computable demonstrates the feasibility of using 
similar methods to annotate drug-drug interaction information. Indeed, our group is already 
attempting this as part of Dr. Richard Boyce’s R01 titled “Addressing gaps in clinically useful 
evidence on drug-drug interactions”. In theory, these methods could be applied to the 
information contained in product labels as a whole, making them searchable, computable, and 
far more accessible to clinicians. Guidance, recommendations, clinical study data, and adverse 
events: all of these clinically relevant pieces of information from a source with regulatory 
authority can support clinical decision making more directly if only they were structured and 
computable.  
Informatics research cannot achieve this alone: it requires a concerted effort from 
experts in many fields: domain experts, particularly pharmacists; clinical researchers to 
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determine the best, evidence-based care guidelines that can be tailored precisely to patients; 
knowledge translation and implementation science researchers to build and install new 
information resources; and of course, health care workers on the ground working out the bugs 
as they will inevitably arise. The technology, the information model, even the information itself 
is not enough to move pharmacogenomics into standard practice. For pharmacogenomics 
knowledge to be used effectively, it must be connected effectively to actual patients and their 
information, in a way that does not burden clinicians with a heavier alert load than they already 
have. 
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6.0  CONTRIBUTIONS 
This thesis is innovative and novel in three ways. We built a novel, clinically relevant semantic 
model. We used qualitative methodologies to elicit 36 pharmacogenomics information needs in 
4 themes and 3 areas of resource requirements of pharmacists, and then applied that 
knowledge to the redesign of the prototype interface. Finally, we evaluated the resource and 
demonstrated that the redesigned interface is more usable in terms of task completion time, 
correctness, and perceived usability than gold standard alternatives. 
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APPENDIX A 
Preliminary Use Cases 
Meet the Clinicians 
Matt the Pharmacist: Matt is a pharmacist in UPMC Presbyterian Hospital’s central 
pharmacy. He has been a pharmacist for 5 years, and is aware of pharmacogenomics and the 
effects genotypes can have on different drugs. He tries to incorporate pharmacogenomics 
information and data into his practice, because he wants to both optimize patient care and 
safety, and protect his license. He is familiar with clinical information sources like UPMC’s 
electronic medical record system, Micromedex, and PubMed. 
Lauren the Hospital Physician: Lauren is a 2nd year cardiology resident in UPMC 
Presbyterian Hospital. She learned about pharmacogenomics in medical school, and is aware of 
the drugs that she prescribes to her patients that have pharmacogenomics implications. She 
would like to incorporate pharmacogenomic genetic tests into her medication prescribing 
workflow, but is unsure of what genetic tests to order, how to order them, and what to do with 
the results. She also is not certain of all the drugs that might require a genetic test. She is 
familiar with clinical information sources like UPMC’s electronic medical record system, 
Micromedex, and PubMed.  
Janet the Hospital Nurse: Janet is a registered nurse in UPMC Presbyterian Hospital. She 
has worked as a nurse for 20 years. She occasionally sees genetic test results in her patients’ 
charts, and would like to understand what the tests are for, and what the results mean. She 
also recently attended a seminar that discussed pharmacogenomics and wants to know if these 
tests could help her patients avoid problems like bleeding while on Warfarin.  
Howard the Patient: Howard is a 64 year old African-American male who recently had a 
stent placed. He also has type II diabetes, and has experienced 2 minor heart attacks in the last 
3 years.  
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The Situation 
 
Matt, Lauren, and Janet are on morning rounds on the cardiac floor of UPMC 
Presbyterian Hospital. They are in Howard’s room discussing adding clopidogrel to his 
medication regimen to avoid clots.  
Use Case 1:  
Matt is using his mobile device to find and share medication information. He also has 
access to the EMR system via a computer on wheels work station. Lauren asks Matt what they 
should know about clopidogrel, specifically how it relates to possible genotypes that Howard 
might have. She recently read an article discussing genetic testing and its importance in certain 
ethnic populations prior to prescribing the drug. She cannot remember the gene variant, or if it 
was prevalent in Asian- or African-American populations, or both. She wants easy access to 
information about clopidogrel and gene variants that affect it in ethnic populations, so she can 
decide whether or not to order the genetic test for her patient. She has looked for 
pharmacogenomics-related information on the UPMC intranet information resources, but has 
not been able to find answers to her questions. In general, she wants to know if any new 
information has been released about drugs and genetic variants that she should know. 
To answer this, Matt wants information about the drug, specifically the presence of 
important genotypes that could predict the patient’s response before he fills the prescription, 
how frequent they are in the African-American population, whether the patient has been 
tested for any of those genotypes, and what the results are, if the test has been performed, 
what the results of the test might mean, and if/how the treatment should be changed based on 
the results. He tries using other resources to answer these questions, such as UPMC’s intranet 
resources, Micromedex, Lexicomp, and Up-to-Date, but they don’t answer his questions in a 
comprehensive, clinically actionable way. 
Lauren mentions other resources she recently heard about in a seminar on 
pharmacogenomics, PharmGKB and GeneTests. When they went to those websites, the 
information presented did not answer their questions clearly and they gave up. Lauren 
consulted her attending physician, who tells her to order a genetic test for CYP2C19 based on 
new recommendations from UPMC. 
 Situation Feature: Mobile Device 
 Pros: Provides mobile access to various information resources. 
Cons: None of the information resources he can access with the mobile device 
answer his question in a way he can quickly parse, understand, and share with the other 
clinicians on rounds. 
 Situation Feature: Computer work station 
Pros: Provides access to extensive patient information via the EMR, as well as 
access to other information resources. Organizes Matt’s workflow in a familiar tool that 
he is used to using. 
Cons: The information Matt is looking for is not available in the EMR or other 
information resources. He has to leave the UPMC intranet to find any information about 
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pharmacogenomics, and he has a hard time understanding the information he finds in 
other resources. 
 
Use Case 2: 
Lauren asks Janet (the nurse) to look for genetic test results for Howard for CYP2C19, 
and make sure she knows when they arrive. Janet has never heard of the test, and wants 
information about its indication, use, and explanation of the results. She looked in the EMR but 
did not find this information in the test order set.  
 Situation Feature: EMR order set 
Pros: Provides standardized, electronic protocol for ordering things like genetic 
tests, that a nurse can submit the order without having much understanding of the test 
or its results.  
Cons: Provides no useful contextual information about the genetic test to a non-
expert, nor does it provide any links to other resources.  
 
Use Case 3: 
Later that week, Matt is verifying medication orders. He receives an alert informing him 
that Howard had tested positive for a genotype, CYPC2C19*2/*2 that can result in an 
undesirable response in patients taking clopidogrel. He wants information about how severe 
Howard’s response could be, how likely it is that he will experience an adverse medication 
event as a result, what the adverse medication event is likely to be, whether he should 
recommend that Lauren switch to a different treatment, and what the change ought to be 
(different drug, or different dose). 
 Situation Feature: Computerized alert 
 Pros: Provides information in a familiar format.  
Cons: The information Matt is looking for is not available in this format, nor is it 
available in the EMR or other information resources. He has to leave this system to find 
any information about pharmacogenomics, and he has a hard time understanding the 
information he finds in other resources. 
Note: This situation is not currently a reality within UPMC as far as I know, since genetic 
tests are not being performed, nor are there alerts presenting the results. 
 
Use Case 4:  
Lauren also receives the CYP2C19 test result for Howard. Lauren wants to know quickly 
what the CYP2C19*2/*2 result means, and what the implications are for her patient, specifically 
clopidogrel, but also the other drugs Howard is currently taking. She knows this variant is 
concerning for clopidogrel, but does not know if it increases or decreases its effectiveness, and 
whether she should give the patient a higher or lower dose. She cannot map the variant to 
clinical implications.  
 Situation Feature: Pharmacogenomics genetic test result 
 Pros: Provides the factual information for the clinician to do with as he or she 
pleases. 
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Cons: Provides very little useful contextual information beyond that. Clinician is 
expected to either know the relevant information, or be able to acquire and understand 
it. Clinician may not be able to easily make an informed decision about what to do as a 
result of this genotype.  
 
Use Case 5: 
Lauren has discontinued Howard’s simvastatin and wants to know if it is okay to 
prescribe another statin like pravastatin for him, considering the gene variant. She would also 
like information about all drugs that are affected by this gene variant, to double check the other 
drugs the patient is taking, and be able to reference in the future for other drugs she might 
need to prescribe. She spent some time on Google, and found the FDA’s Table of 
Pharmacogenomic Biomarkers In Drug Labels 
(http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.ht
m). It told her the list of all drugs that might be impacted by the CYP2C19 genotype, but no 
information about this specific variant. She is not sure where to find information that detailed. 
When she looks at the sections the list mentions in the drug labels, she does not find any 
recommendation information. 
 Situation Feature: FDA’s Table of Pharmacogenomic Biomarkers In Drug Labels 
Pros: Reliable, trust-worthy list of all the biomarkers and associated medications 
that the FDA has deemed worthy of placing warnings in drug labels. Can be reordered 
by drug or biomarker. 
Cons: Limited information provided. No information about specific variants, nor 
any links to other resources that might provide that information. No recommendation 
information 
Situation Feature: Structured product labels 
Pros: Detailed set of information about drugs, including information about 
pharmacogenomics biomarkers. 
Cons: Difficult to read, understand, or find the relevant information a clinician 
might be seeking quickly. Pharmacogenomics biomarkers information does not provide 
recommendations.  
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APPENDIX B 
Semi-structured interview questions: 
1. General demographics: age, gender, ethnicity, number of years as a pharmacist, number
of years at UPMC, job role
a. Age
i. 18-35
ii. 36-50
iii. 51-65
iv. >65
b. Gender
i. Male
ii. Female
c. Ethnicity
i. African-American
ii. Asian-American
iii. Caucasian
iv. Hispanic
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v. Other  
d. Number of years as a pharmacist 
i. <5 
ii. 5-15 
iii. 16-25 
iv. >25 
e. Number of years as a pharmacist at UPMC 
i. <5 
ii. 5-15 
iii. 16-25 
iv. >25 
2. What is your job title? 
3. What major tasks do you do in a normal day?  
4. Approximately how many prescriptions do you fill in an average day? 
5. What percentage of prescriptions do you manage that require you to find additional 
information? 
6. Regarding question 3, what information do you need? How do you find it, usually? Show 
me. 
7. Where do you go to find the following information: 
a. Drug effectiveness 
b. Drug Safety 
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c. Monitoring requirements 
d. Drug indications 
e. Guidelines about the drug 
f. Recommendations from a clinical pharmacist 
8. Can you give me an example of a time that you had a difficult time getting drug 
information? What happened? Show me. 
9. Why do you use the resources that you do? 
10. Approximately how many times on average per day do you participate in a drug 
prescription decision?  
11. How many of these decisions require that you look up information about the 
medications in question?  
12. Where do you look? Show me. 
13. What do you like about the resources? 
14. What do you dislike about the resources? 
15. Have you had professional exposure to pharmacogenomics? Yes/no 
Questions 16-18 only for people who answer “yes” to question 12. 
16. How would you describe that exposure? 
17. Do you anticipate that pharmacogenomics will have a growing impact on your 
profession soon? How so? 
18. Do pharmacogenomics considerations play a role in your work?  
19-28 only if answer to 18 is yes 
19. How frequently do pharmacogenomics considerations play a role in your work? 
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20. When you are considering medications with pharmacogenomics implications, how 
frequently (i.e., what percentage of the time) do you need to find additional information 
to assist in your decision-making? 
21. What types of information do you need?  
22. How do you find it, usually? Show me 
23. Can you give me an example of a time that you had difficult time getting 
pharmacogenomics information? What happened?  
24. Where did you look for information?  
25. Why were those resources inadequate? 
26. How many patients that you manage have had pharmacogenomic test results in their 
charts (in the last year?)? 
27. Have you ever recommended pharmacogenomics testing? Yes/no 
28. If yes: For how many patients have you recommended pharmacogenomics testing (in 
the last year?)? 
Interactive: 
We are developing information tools that provide clinically-focused information about 
pharmacogenomics and related drugs to clinicians. To develop these tools, we would like to 
understand how you make prescription decisions about drugs in general, and about drugs that have 
pharmacogenomics implications. To do this, we would like you to think about a hypothetical patient, 
show us how you would find information to manage this patient currently, and then demo our 
information tool prototype to find that information. Afterward, we will ask you some follow-up 
questions.  
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29. Without POC: 
a. Say you have a patient named Howard, a 64 year old African-American male who 
recently had a stent placed. He also has type II diabetes, and has experienced 2 
minor heart attacks in the last 3 years. His physician is considering prescribing 
clopidogrel. What do you think is important to know before prescribing 
clopidogrel, that isn’t already available in the EMR? 
b. Where would you go to acquire that information? Show me. 
c. Howard’s physician orders a genetic test for Howard’s CYPC2C19 status, and his 
variant is CYPC2C19*2/*2. What does this information tell you about prescribing 
clopidogrel? 
d. What information do you think that you might want to learn about that variant 
with respect to that drug?  
e. Where would you go to acquire that information? Show me. 
f. What do you like about how the resource(s) presents drug information? 
g. What do you dislike about how the resource(s) presents drug information? 
h. What do you like about how the resource(s) presents genotype information? 
i. What do you dislike about how the resource(s) presents genotype information? 
j. Is there information you would like, but cannot find in the resource(s)? 
k. Do/Does this/these resource(s) provide you with the information that you need 
to feel comfortable in prescribing this medication? 
l. Do you have any other comments about this resource(s)? 
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30. On POC: 
a. This is an information resource we’re developing to provide pharmacogenomics 
information to clinicians. Consider Howard, the patient mentioned above. Using 
this resource, where would you go to acquire that same information? 
(clopidogrel information and genotype information) 
b. What do you like about how this resource presents drug information? 
c. What do you dislike about how this resource presents drug information? 
d. What do you like about how this resource presents genotype information? 
e. What do you dislike about how this resource presents genotype information? 
f. Is there information you would like, but cannot find in this resource? 
g. Do/Does this/these resource(s) provide you with the information that you need 
to feel comfortable in prescribing this medication?  
h. Do you have any other comments about this resource? 
31. Do you have any concerns or general comments?  
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APPENDIX C 
Complete Codebook from Qualitative Inquiries 
Name Sources References 
Information need 14 457 
Background Information 4 4 
Insurance information 3 5 
Location of information 1 2 
medical condition 7 12 
Allergies 3 3 
Bleeding risk 1 1 
Patient's weight 1 1 
medication information 14 430 
Additive information 1 1 
Comparative effectiveness 3 6 
Concomitant medications 9 11 
Contraceptive information 1 1 
Dispensing information 2 2 
dosing 8 18 
Drug availability 2 3 
Drug compatibility 2 2 
Drug efficacy 12 20 
Drug equivalency 1 2 
Drug identification 1 1 
Drug indications 13 21 
Drug Safety 13 51 
Adverse effects 10 29 
Drug-drug interactions 7 17 
Frequency of interaction 1 1 
Severity of interaction 3 3 
Side effects 1 3 
Drug toxicity 3 6 
Evidence 2 2 
Guidelines about the drug 13 13 
IV information 5 7 
IV compatibility 2 2 
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IV extravasation instructions   1 1 
IV stability   1 2 
Length of time taking medication   1 1 
Mechanism of action   1 1 
Medication previously taken   1 1 
Monitoring requirements   13 16 
Novel drug   1 1 
Off-label use   3 3 
Other drugs in same class   4 4 
Patient population-specific information   1 1 
Pharmacodynamics   1 1 
Pharmacogenomics information   14 188 
Other drug(s) affected by biomarker   5 5 
Pharmacogenomics background information   10 14 
Pharmacogenomics evidence   6 12 
Pharmacogenomics guidelines   6 14 
Phenotype information   14 39 
Severity of pharmacogenomics risk   4 7 
test information   8 14 
Test parameters   2 3 
variant information   13 51 
Population frequency   3 5 
Pharmacokinetics   2 3 
Drug elimination   1 1 
Drug Metabolism   1 1 
Price   3 4 
protocol information   0 0 
QTc interval   2 2 
recommendation   14 40 
Alternative drug choices   6 10 
Patient preferences   1 1 
Information source   1 1 
Benefit of tool or resource   14 244 
Available   6 6 
Available online   1 1 
Clinically relevant   5 6 
Contains visualizations   6 6 
Credible   5 6 
Disease-focused   1 1 
Easy to use   14 93 
Current   1 1 
Familiar   8 9 
Good mobile version   1 1 
Organized   12 28 
Quick   13 23 
Free   2 4 
Good reputation   3 3 
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Helpful   2 3 
Information benefit   14 105 
Accurate   4 5 
Concise   12 26 
Contains pharmacogenomics information   6 9 
Objective   1 1 
Peer-reviewed   1 1 
Provide references or citations   6 11 
Provides background information   4 5 
Provides comparisons   1 1 
Provides links to other resources   3 3 
Provides off-label indications   1 1 
Provides recommendations   9 19 
Regularly updated   2 2 
Thorough   10 20 
Necessary   2 2 
Preferred by physicians   1 1 
Provides full text   1 1 
Reliable.   2 3 
Book   5 5 
Managing Contraception   1 1 
Clinical pharmacist   8 12 
Digital Information Resource   14 400 
CDC   1 1 
FDA   8 36 
FDA Table of Pharmacogenetic Biomarkers   1 1 
Product label   6 28 
DailyMed   1 4 
Medwatch   1 1 
PGXatPitt   14 51 
PharmGKB   1 5 
CPIC guidelines   1 5 
Primary literature   13 63 
Pubmed   11 43 
Case reports   1 3 
Clinical trials   7 16 
Professional society   5 11 
Beers Criteria   1 1 
Clinical guidelines   2 3 
Search engine   5 6 
Google   4 5 
Tertiary resources   14 224 
Access medicine   1 1 
AHFS Drug Information   1 10 
Clinical Key   1 1 
Clinical Pharmacology   3 8 
CredibleMeds (AZCert)   1 1 
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Dynamed   2 8 
Facts and Comparisons   3 5 
GlobalRPH   2 4 
Hippocrates   4 13 
Johns Hopkins ABX Guide   1 1 
Lab Values   0 0 
Lexicomp   10 57 
Micromedex   13 67 
Pharmacists' Letter   1 5 
Prescriber's Letter   1 1 
RXpertise   2 3 
Skyscape   1 4 
STATRef   1 1 
UpToDate   7 28 
Drug company   5 7 
Electronic medical record   1 1 
Internal information resource   2 3 
Journal   0 0 
Patient   1 1 
PDA   1 1 
Problem with tool or resource   14 206 
Biased   1 1 
Difficult to use   14 64 
Bad mobile version   3 3 
Disorganized   6 9 
Does not divide drugs by specialty   1 1 
Information overload   10 22 
Verbose   9 15 
Information poorly displayed   7 10 
Problems with workflow   4 4 
Slow   5 6 
Unfamiliar   2 2 
Information problem   14 126 
Confusing   6 9 
Difficulty finding information   14 99 
Difficult to search   2 2 
Lacking information   13 76 
Information not published   1 1 
Lack of evidence   3 5 
Lacks background information   6 8 
Lacks dosage information   3 4 
Lacks full text articles   1 1 
Lacks indication about severity of implications   2 2 
Lacks information about validity of clinical studies   2 2 
Lacks IV compatibility   1 2 
Lacks links to other resources   4 5 
Lacks off-label indications   1 2 
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Lacks patient education   1 1 
Lacks pharmacogenomics information   5 7 
Lacks recommendations   7 13 
Lacks source of information   5 9 
Must leave database to get complete info   3 3 
Problems with terminology or search terms   6 9 
Inaccurate   4 4 
Inconsistent   1 2 
Out of date   5 5 
Repetitive   1 1 
Subjective opinion   3 5 
Lacks source of information   2 4 
Lacks visualization   1 1 
Resource unavailable   1 1 
Unnecessary   0 0 
Pharmacogenomics experience   1 1 
Clinician exposure to pharmacogenomics   12 22 
Current state of pharmacogenomics   1 2 
Pharmacogenomics currently unavailable   1 1 
Unaware of where pharmacogenomics information is   1 1 
Educational exposure to pharmacogenomics   4 7 
Graduate   3 4 
Undergraduate   0 0 
Professional exposure to pharmacogenomics   10 12 
CME   1 1 
None   1 1 
On the job   3 3 
Reading literature   2 2 
Research   1 1 
Seminar   1 1 
Effect on practice   8 10 
Economic changes   2 4 
Increase in information   9 22 
Change in formulary decisions   1 2 
Change in treatment decisions or recommendations   5 9 
Outcome changes   6 6 
Negative outcome changes   0 0 
Positive outcome changes   1 1 
Unknown outcome changes   1 1 
Workflow changes   5 5 
Pharmacy Task   14 73 
Chart review   7 12 
Lab value review   2 2 
Community pharmacy practice   2 2 
Patient care   2 2 
Consulting   8 16 
Patient follow-up   1 1 
113 
Provide therapy recommendations 5 7 
Providing drug information 3 3 
Drug monitoring 2 3 
Formulary management 1 2 
Medication reconciliation 1 3 
Order entry 4 5 
Order verification 4 5 
Patient education 1 1 
Pharmacy support 2 2 
Prescription claims management 1 3 
Prescription filling 2 3 
Research 1 1 
Rounding 4 8 
Teaching students 2 4 
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